thiazoles has been researched along with Parkinson Disease in 261 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.38) | 18.7374 |
| 1990's | 39 (14.94) | 18.2507 |
| 2000's | 147 (56.32) | 29.6817 |
| 2010's | 68 (26.05) | 24.3611 |
| 2020's | 6 (2.30) | 2.80 |
| Authors | Studies |
|---|---|
| Karnam, M; Thamaraikani, T; Velapandian, C | 1 |
| Chakra, MA; Dabboucy, B; Dellis, A; Fares, Y; Moussa, M; Papatsoris, A | 1 |
| Tavassoly, O; Vocadlo, DJ; Yue, J | 1 |
| Gu, L; Huang, YL; Wang, Y; Yang, HM; Zhang, H; Zhang, JN | 1 |
| Cho, SY; Choo, MS; Jeong, SJ; Kim, J; Lee, S; Lee, SH; Oh, SJ | 1 |
| Collins-Praino, LE; Corrigan, F; Guglietti, B; Mustafa, S; Sivasankar, S | 1 |
| Agrawal, S; Kumari, N; Luthra, PM | 1 |
| Ensom, MHH; Johnson, EG; Johnson, HE; Wilby, KJ | 1 |
| Bishop, C; Conti, MM; Das, B; Dutta, AK; Lindenbach, D; Meadows, SM | 1 |
| Benavides, GA; Chatham, JC; Cofield, SS; Darley-Usmar, V; Ouyang, X; Redmann, M; Shacka, JJ; Wani, WY; Zhang, J | 1 |
| Abdelhameed, AS; Khan, RH; Masroor, A; Neelofar, K; Nusrat, S; Siddqi, MK; Zaidi, N; Zaman, M | 1 |
| Baker, SL; Boxer, AL; Devous, MD; Dickerson, BC; Gomperts, SN; Grinberg, LT; Grossman, M; Jagust, WJ; Johnson, KA; Kramer, JH; Litvan, I; McMillan, CT; Miller, BL; Nasrallah, I; Pressman, P; Rabinovici, GD; Roberson, ED; Russell, DS; Schonhaut, DR; Seeley, WW; Siderowf, A; Spina, S; Tsai, R; Winer, J | 1 |
| Dahl, R; Krajnak, K | 1 |
| Chen, SF; Kuo, HC | 1 |
| Agrawal, S; Kumari, N; Kumari, R; Luthra, PM; Sharma, D | 1 |
| Abeyawardhane, DL; Crozier, MK; Fernández, RD; Forney, AK; Heitger, DR; Lucas, HR; Murgas, CJ | 1 |
| Bartenstein, P; Brendel, M; Hanaoka, K; Hosokawa, C; Ishii, K; Kaida, H; Murakami, T; Rominger, A; Sauerbeck, J; Scheiwein, FT | 1 |
| Biagioni, MC; Brucker, BM; Feigin, A; Frucht, S; Gilbert, R; Kaufmann, H; Malacarne, DR; Nitti, VW; Palma, JA; Palmerola, R; Peyronnet, B; Rosenblum, N; Sussman, RD; Vurture, G | 1 |
| Black, KJ; Davis, AA; Younce, JR | 1 |
| Clement, N; Frosch, M; Gomez-Isla, T; Gomperts, SN; Growdon, JH; Johnson, KA; Katz, S; Schultz, A; Shirvan, J; Ye, R | 1 |
| Egoz-Matia, N; Frenkel-Pinter, M; Gazit, E; Levy-Sakin, M; Masliah, E; Patrick, C; Rockenstein, E; Schiller, A; Segal, D; Shaltiel-Karyo, R | 1 |
| Choo, H; Choo, IH; Jo, S; Keum, G; Kim, J; Kim, T; Lee, CJ; Lee, J; Lim, EJ; Min, SJ; Moon, B; Nam, G; Park, HR; Park, KD; Yeom, M | 1 |
| Eidelberg, D; Martin, W | 1 |
| Cairns, NJ; Campbell, MC; Flores, H; Goate, AM; Hartlein, JM; Markham, J; Perlmutter, JS; Videen, TO | 1 |
| Dutta, A; Johnson, M; Santra, S; Shah, M; Xu, L | 1 |
| Di Paolo, T; Morissette, M; Parent, M; Riahi, G; Samadi, P | 1 |
| Casadei, N; De Heer, R; Kahle, PJ; Klucken, J; Krüger, R; Lucas, JJ; Noldus, LP; Nuber, S; Pöhler, AM; Riess, O; Schwedhelm, I; Spruijt, B; Tomás-Zapico, C; Torres-Peraza, J; Witz, A; Zamolo, I | 1 |
| Cheng, D; Hu, JY; Li, Z; Liu, J; Liu, YY; Liu, ZL; Wang, HJ; Wang, LM; Wang, Y; Wen, XJ; Yang, XY | 1 |
| Antonio, T; Dutta, A; Modi, G; Reith, M | 1 |
| Alcacer, C; Bimpisidis, Z; Cenci, MA; Engblom, D; Fieblinger, T; Maslava, N; Sandberg, S; Sebastianutto, I | 1 |
| Albin, RL; Bohnen, NI; Constantine, GM; Frey, KA; Koeppe, RA; Kotagal, V; Müller, ML; Scott, PJ; Studenski, S | 1 |
| Hassan, HE; Kong, L; Li, T; Liu, J; MacKerell, AD; Park, JS; Smith, WW; Thomas, JM; Voulalas, P; Xue, F; Yang, D; Zhong, S | 1 |
| Lu, BX; Luo, YF; Man, RY; Wang, XF; Zeng, QG; Zeng, Y | 1 |
| Abalde-Atristain, L; Dawson, TM; Dawson, VL; Kim, JW; Martin, I | 1 |
| Buddhala, C; Campbell, MC; Koller, JM; Kotzbauer, PT; Perlmutter, JS; Snyder, AZ | 1 |
| Gao, Q; Ou, Z; Tong, Q; Wu, L; Zhang, Y; Zhu, D | 1 |
| Dutta, AK; Shah, M; Voshavar, C; Xu, L | 1 |
| Albin, RL; Bohnen, NI; Frey, KA; Koeppe, RA; Kotagal, V; Müller, ML; Petrou, M; Scott, PJ; Shah, N | 1 |
| Chao, J; Chen, N; Gong, W; Li, X; Ma, J; Wu, M; Yang, H; Zhao, Y | 1 |
| Cremades, N; Dalla Serra, M; Dear, AJ; Dobson, CM; Horrocks, MH; Klenerman, D; Knowles, TP; Tosatto, L | 1 |
| Bayer, S; Gomperts, SN; Growdon, JH; Johnson, KA; Locascio, JJ; Marquie, M | 1 |
| Beckwith, JS; Chen, SW; Cremades, N; Devine, MJ; Dobson, CM; Gandhi, S; Horrocks, MH; Iljina, M; Kjaergaard, M; Klenerman, D; Lee, SF; Magdalinou, NK; Tosatto, L; Wood, NW; Zetterberg, H | 1 |
| Dholkawala, F; Dutta, AK; Voshavar, C | 1 |
| Cheeran, B; Fletcher, C; Murchison, AG | 1 |
| Decossas-Mendoza, M; Krisa, S; Lambert, O; Mérillon, JM; Richard, T; Temsamani, H | 1 |
| Caso, C; Dickerson, BC; Gomperts, SN; Growdon, JH; Johnson, K; Locascio, JJ; Makaretz, SJ; Schultz, A; Sperling, R; Vasdev, N | 1 |
| Bickle, L; Hopwood, JJ; Karageorgos, L | 1 |
| Jain, S; Pandey, S; Sarma, N | 1 |
| Becker, JA; Elmaleh, DR; Fischman, AJ; Gomperts, SN; Growdon, JH; Hyman, BT; Johnson, KA; Klunk, WE; Locascio, JJ; Mathis, CA; Moran, E; Rentz, DM; Shoup, T | 1 |
| Alam, MM; Anwer, T; Azam, F; Barodia, SK | 1 |
| Fink, AL; Hong, DP; Uversky, VN | 1 |
| Becker, C; Berg, D; Gasser, T; Keller, S; Leyhe, T; Liepelt, I; Maetzler, W; Melms, A; Reimold, M; Reischl, G; Schulte, C; Solbach, C | 1 |
| Chiappe, D; Grimminger, V; Hang, I; Lashuel, HA; Moniatte, M; Pignat, V; Schmid, AW | 1 |
| Hirohata, M; Ikeda, T; Morinaga, A; Ono, K; Yamada, M | 1 |
| Antonio, T; Dutta, AK; Ghosh, B; Kharkar, P; Reith, ME; Zhen, J | 1 |
| Burack, MA; Cairns, NJ; Flores, HP; Hartlein, J; Perlmutter, JS; Taylor-Reinwald, L | 1 |
| Ahmad, A | 1 |
| Giehm, L; Otzen, DE | 1 |
| Björklund, A; Brundin, P; Englund, E; Li, JY; Lindvall, O; Rehncrona, S; Widner, H | 1 |
| Bae, SY; Hwang, H; Kim, HK; Kim, JH; Kim, S; Kim, TD; Lee, S; Yoon, HC | 1 |
| Aalto, S; Haaparanta, M; Jokinen, P; Någren, K; Parkkola, R; Rinne, JO; Rokka, J; Röyttä, M; Savisto, N; Scheinin, N | 1 |
| Burack, MA; Cairns, NJ; Campbell, MC; Flores, HP; Foster, ER; Hartlein, J; Hershey, T; Perlmutter, JS | 1 |
| Chang, JY; Hong, DP; Jiang, C; Xiong, W | 1 |
| Binaglia, L; Calabresi, P; Chiasserini, D; de Iure, A; Koya, K; Orvietani, PL; Susta, F; Tantucci, M; Tozzi, A | 1 |
| Cook, AL; Mackay-Sim, A; Matigian, N; Mellick, GD; Perry, C; Ravishankar, S; Shan, J; Silburn, PA; Sutharsan, R; Sutherland, GT; Vitale, AM; Wells, CA; Whitelaw, ML; Wood, SA | 1 |
| Arnaldi, D; Brugnolo, A; Campus, C; Ferrara, M; Mazzei, D; Mehrdad, N; Morbelli, S; Nobili, F; Rodriguez, G; Sambuceti, G | 1 |
| Buongiorno, M; Compta, Y; Martí, MJ | 1 |
| Alcaro, S; Bolasco, A; Cardia, MC; Distinto, S; Gaspari, M; Kirchmair, J; Maccioni, E; Markt, P; Meleddu, R; Ortuso, F; Sanna, ML; Secci, D; Wolber, G; Yáñez, M | 1 |
| Bajpai, M; Banerjee, A; Gharat, LA; Gudi, GS; Gullapalli, S; Sangana, RR; Yadav, PS | 1 |
| Bannach, O; Birkmann, E; Funke, SA; Hübinger, S; Willbold, D | 1 |
| Asari, M; Awaya, T; Kimura, N; Matsubara, K; Noda, T; Ohkubo, T; Ohtaki, K; Omura, T; Ono, T; Sakaguchi, T; Shimizu, K; Suno, M; Tasaki, Y; Yamamoto, J | 1 |
| Gomperts, SN; Growdon, JH; Johnson, KA; Locascio, JJ; Marquie, M; Maye, J; Rentz, DM; Santarlasci, AL | 1 |
| Dikiy, I; Eliezer, D; Fares, MB; Fauvet, B; Lashuel, HA; Samuel, F; Tandon, A | 1 |
| Arduino, DM; Cardoso, SM; Esteves, AR; Januario, C; Martins-Branco, D; Oliveira, CR; Santos, D; Swerdlow, RH | 1 |
| Fukushi, K; Higuchi, M; Hirano, S; Irie, T; Ito, H; Kuwabara, S; Miyoshi, M; Ota, T; Sato, K; Shimada, H; Shinotoh, H; Suhara, T; Tanaka, N | 1 |
| Albin, RL; Bohnen, NI; Frey, KA; Koeppe, RA; Kotagal, V; Müller, ML; Petrou, M | 1 |
| Gomperts, SN; Growdon, JH; Johnson, KA; Locascio, JJ; Marquie, M; Rentz, D; Santarlasci, A | 1 |
| Aron Badin, R; Auguet, M; Bertrand, A; Boulet, S; Brouillet, E; Chabrier, PE; Dollé, F; Gaillard, MC; Guillermier, M; Hantraye, P; Jan, C; Malgorn, C; Savasta, M; Spinnewyn, B; Van Camp, N | 1 |
| Kopito, RR; Melki, R; Quake, SR; Sourigues, Y; Streets, AM | 1 |
| Brucale, M; Bubacco, L; Codolo, G; de Bernard, M; Plotegher, N; Pozzobon, T; Tessari, I | 1 |
| Ahlskog, JE; Maraganore, DM; Uhl, GR; Uitti, RJ | 1 |
| Schulz, GM | 1 |
| Montgomery, EB | 2 |
| Brecht, HM; Kraus, PH; Lemke, MR; Reichmann, H | 1 |
| Gekht, AB | 1 |
| Crevenna, R; Homann, CN; Ivanic, G; Ott, E; Suppan, K; Wenzel, K | 1 |
| Schapira, AH | 2 |
| Jennings, D; Marek, K; Seibyl, J | 1 |
| Clarke, CE; Guttman, M | 1 |
| Reichmann, H | 1 |
| Andrén, PE; Arts, J; Gunne, L; Jongsma, M; Klintenberg, R; Wikström, H | 1 |
| Kuhlmann, A; Müller, T; Przuntek, H | 1 |
| Bain, PG; Findley, LJ; Jeffs, JA; Navan, P; Pearce, RK | 2 |
| Berardelli, A; De Pandis, MF; Modugno, N; Ruggieri, S; Stocchi, F; Thomas, A; Vacca, L; Valente, M | 1 |
| Bergmans, P; Booij, J; Stoof, JC; van Royen, EA; Winogrodzka, A; Wolters, EC | 1 |
| Bassi, A; Boffa, L; Brusa, L; Caramia, MD; Peppe, A; Pierantozzi, M; Ruggieri, S; Stanzione, P; Stefani, A | 1 |
| Etminan, M; Gill, S; Samii, A | 1 |
| MacMahon, DG | 1 |
| Morrish, PK | 1 |
| Bares, M; Dostál, V; Ehler, E; Fanfrdlová, Z; Fiedler, J; Klajblová, H; Kulist'ák, P; Rektor, I; Rektorová, I; Ressner, P; Svátová, J; Urbánek, K; Velísková, J | 1 |
| Choi, DK; Jackson-Lewis, V; Przedborski, S; Teismann, P; Tieu, K; Vila, M; Wu, DC | 1 |
| Driver-Dunckley, E; Samanta, J; Stacy, M | 1 |
| Fleckenstein, AE; Hanson, GR; Rau, KS; Truong, JG | 1 |
| Inzelberg, R; Nisipeanu, P; Schechtman, E | 1 |
| Barone, P | 1 |
| Brecht, MH; Köster, J; Kraus, PH; Lemke, MR; Reichmann, H | 1 |
| Hasegawa, K; Kowa, H; Kuno, S; Mizuno, Y; Origasa, H; Yamamoto, M; Yanagisawa, N | 1 |
| Lu, CS; Mok, V; Shan, DE; Tsoi, TH; Wong, KS; Yang, CC | 1 |
| Finsterer, J; Gatterer, E; Stöllberger, C | 1 |
| Lang, AE; Razmy, A; Shapiro, CM | 1 |
| Krahn, M; Lang, A; Marras, C; Naglie, G; Tomlinson, G | 1 |
| Jankovic, J; Le, W; Pan, T | 1 |
| Connemann, BJ; Schönfeldt-Lecuona, C | 1 |
| Chigir', IP; Fedorova, NV; Krivonos, OV | 1 |
| Linazasoro, G | 1 |
| Gray, NS | 1 |
| Fernández, CO; Griesinger, C; Hoyer, W; Jares-Erijman, EA; Jovin, TM; Subramaniam, V; Zweckstetter, M | 1 |
| Kohno, Y; Takeuchi, S | 1 |
| Alexander-Brown, B; Atassi, F; Barclay, L; Bennett, S; Berry, D; Biglan, K; Borchert, L; Brocht, A; Brown, D; Daigneault, S; DeAngelis, M; Dillon, S; Dobson, J; Evans, S; Factor, S; Fahn, S; Fontaine, D; Ford, B; Fussell, B; Hall, J; Hammerstad, J; Harrigan, M; Hodgeman, K; Holloway, RG; Hubble, J; Jankovic, J; Kamp, C; Kieburtz, K; Kurlan, R; Lang, A; LeWitt, P; Marek, K; McDermott, M; Miyasaki, J; Montgomery, A; Musch, B; O'Connell, C; Pahwa, R; Panisset, M; Pantella, C; Petsinger, G; Pfeiffer, B; Pfeiffer, R; Rainey, P; Rajput, A; Richard, K; Riley, D; Rodnitzky, R; Ross, T; Rost-Ruffner, E; Russell, DS; Seibyl, J; Shinaman, A; Shirley, T; Shoulson, I; Shults, C; Sime, E; Stacy, M; Standaert, D; Suchowersky, O; Sutherland, L; Tennis, M; Waters, C; Watts, A; Weeks, C; Weiner, W; Welsh, M; Wood, S; Wooten, F | 1 |
| Antonini, A; Belgrado, E; Bergonzi, P; Cutuli, D; Mucchiut, M | 1 |
| Grosset, D; Grosset, K; Macphee, G; Needleman, F | 1 |
| Cassel, W; Haja, D; Körner, Y; Krüger, HP; Meindorfner, C; Möller, JC; Oertel, WH; Stiasny-Kolster, K | 1 |
| Bara-Jimenez, W; Chase, TN; Dimitrova, T; Favit, A; Mouradian, MM; Sherzai, A | 1 |
| Borwege, S; Hagner, D; Joyce, JN; Ryoo, H; Woolsey, C | 1 |
| Katz, IR | 1 |
| Bain, PG; Findley, LJ; Navan, P; Pearce, RK; Undy, MB | 1 |
| Fukuhara, Y; Ishitani, R; Katsube, N; Kuwae, T; Mizuno, Y; Mochizuki, H; Nakano, T; Nakashima, K; Ohama, E; Sunaga, K; Tajima, H; Takeshima, T; Tanaka, M; Tsuchiya, K | 1 |
| Köster, J; Möller, JC; Oertel, WH; Pezzoli, G; Provinciali, L | 1 |
| Boggie, DT; Chan, H; Delattre, ML; Morreale, AP; Plowman, BK; Schaefer, MG | 1 |
| Kurlan, R | 1 |
| Ahmad, R; Beilina, A; Bergantino, E; Bubacco, L; Carter, D; Clarimon, J; Cookson, MR; Costin, GE; Eerola, J; Greggio, E; Hearing, VJ; Hellström, O; Miller, DW; Singleton, A; Tienari, PJ | 1 |
| Korchounov, A; Oechsner, M | 1 |
| Althoff, R; Jacobson, J; Martineau, RJ; Singh, A | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Chung, KC; Kim, J; Lee, CH; Lee, HJ; Lee, ST; Oh, YJ; Paik, SR; Park, SM; Sung, JY; Um, JW | 1 |
| Glover, V; Igosheva, N; Lorz, C; Mehmet, H; O'Conner, E | 1 |
| Brecht, HM; Koester, J; Kraus, PH; Lemke, MR; Reichmann, H | 1 |
| Ali, FE; Barnham, KJ; Bottomley, SP; Cappai, R; Cherny, RA; Culvenor, JG; Curtain, CC; Galatis, D; Hill, AF; Leck, SL; Masters, CL; Sharples, RA; Smith, DP; Tew, DJ; Williamson, NA | 1 |
| Asanuma, M; Diaz-Corrales, FJ; Miyazaki, I; Ogawa, N; Shimizu, M; Tanaka, K | 1 |
| Minichiello, L; Unsicker, K; von Bohlen und Halbach, O | 1 |
| Bezard, E; Guo, S; Zhao, B | 1 |
| Gauthier, P; Jankovic, J; Manian, P; Tintner, R | 1 |
| Ginovart, N; Ko, F; McCormick, P; Seeman, P; Willeit, M | 1 |
| Ahlskog, JE; Bower, JH; Josephs, KA; Klos, KJ; Matsumoto, JY | 1 |
| Hosoya, T; Iida, R; Kobayashi, S; Kuriyama, S; Otsuka, Y; Tomita, M | 1 |
| Lin, CL; Luu, SU; Mao, WC; Shiah, IS | 1 |
| Möller, JC; Oertel, WH | 2 |
| Hongo, K; Kawata, Y; Kusaka, E; Mizobata, T; Yagi, H | 1 |
| Stocchi, F | 1 |
| Bodner, N; Edridge, S; Fink, AL; Hong, DP; Kaylor, J; Yamin, G | 1 |
| Alfonso, A; Burnam, L; Hoener, M; Liu, L; Perier, C; Przedborski, S; Rodrigues, CM; Saha, S; Sluder, A; Steer, C; Ved, R; Westlund, B; Wolozin, B | 1 |
| Dick, AW; Holloway, RG; Noyes, K | 1 |
| Barkats, M; Colin, P; Faucon-Biguet, N; Horellou, P; Mallet, J; Millecamps, S | 1 |
| Ishida, Y; Kim, SU; Kobayashi, S; Nagai, A | 1 |
| Brown, LA; Doan, J; Pellis, SM; Suchowersky, O; Whishaw, IQ | 1 |
| Bharmal, A; Lu, C; Suchowersky, O | 1 |
| Morgan, JC; Sethi, KD; Sharma, P | 1 |
| Cenci, MA; Danysz, W; Dekundy, A; Pietraszek, M; Schaefer, D | 1 |
| Lev, N; Melamed, E; Offen, D | 1 |
| Palmieri, A | 1 |
| Altamirano, L; Cools, R; D'Esposito, M | 1 |
| Duda, JE; Goveas, J; Moberg, PJ; Morales, KH; Potenza, MN; Siderowf, AD; Stern, MB; Weintraub, D | 1 |
| Chigir', IP; Fedorova, NV | 1 |
| Schindehütte, J; Trenkwalder, C | 1 |
| Iwashita, A; Kita, Y; Matsuoka, N; Mihara, K; Moriguchi, A; Muramatsu, Y; Muramoto, M; Yamazaki, S; Yamazaki, T | 1 |
| Ono, K; Yamada, M | 1 |
| Askmark, H; Engler, H; Forsberg, A; Johansson, A; Långström, B; Nordberg, A; Savitcheva, I | 1 |
| Duggal, HS; Singh, I | 1 |
| Bares, R; Berg, D; Eschweiler, GW; Gaenslen, A; Gasser, T; Leyhe, T; Liepelt, I; Machulla, HJ; Maetzler, W; Mittelbronn, M; Reimold, M; Reischl, G; Schweitzer, K; Solbach, C; Uebele, M | 1 |
| Calissano, P; Cicconi, S; Ciotti, MT; Gentile, A; Parasassi, T; Serafino, A | 1 |
| Barreto, G; Bertolino, LA; Capani, F; Giraldez, LD; Madureira de Oliveria, D; Saraceno, E; Valverde G De Andrade, D | 1 |
| Danzer, KM; Duan, W; Finger, S; Garidel, P; Giese, A; Glabe, CG; Habeck, M; Heinzelmann, U; Högen, T; Kostka, M; Kretzschmar, H; Levin, J; Ross, CA; Wagner, R; Wirth, A | 1 |
| Kääriäinen, TM; Kekki, H; Lecklin, A; Lehtonen, S; Männistö, PT; Nenonen, T; Ossola, B; Piltonen, M; Raasmaja, A | 1 |
| Kerk, S; Meng Lim, T; Zhou, Z | 1 |
| Camacho-Ochoa, M; Evans, DL; Piercey, MF; Walker, EL | 1 |
| Arendt, T; Bigl, V; Brückner, MK; Marcova, L | 1 |
| Achiron, A; Barzilai, A; Luria, D; Melamed, E; Nardi, N; Offen, D; Ziv, I | 1 |
| Cutler, NR; Elvin, A; Friedman, J; Goetz, C; Hubble, JP; Koller, WC; Korts, D; Ranhosky, A; Sramek, JJ | 1 |
| Rabey, JM | 1 |
| Brown, D; Factor, SA; Molho, ES; Sanchez-Ramos, JR; Sheldon, C; Shulman, L; Singer, C; Weiner, WJ | 1 |
| Hansen, LA; Mallory, M; Masliah, E; Vincent, I; Wakabayashi, K | 1 |
| Klivényi, P; Vécsei, L | 1 |
| Korts, D; Lieberman, A; Ranhosky, A | 1 |
| Heins, JR | 1 |
| Bennett, JP; Friedman, JH; Shannon, KM | 1 |
| Alldredge, BK; Aminoff, MJ; Bainbridge, JL; Dowling, GA; Gottwald, MD | 1 |
| Guttman, M | 1 |
| LeWitt, PA | 2 |
| Force, RW; Ting, RM | 1 |
| Dooley, M; Markham, A | 1 |
| Hashimoto, M; Hsu, LJ; Masliah, E; Sisk, A; Sundsmo, M; Takeda, A; Xia, Y | 1 |
| Fernandez, HH; Friedman, JH | 1 |
| Yamamoto, M | 1 |
| Lange, KW | 1 |
| Curran, MD; El-Agnaf, OM; Jakes, R; Wallace, A | 1 |
| Bianchi, E; Curran, MD; El-Agnaf, OM; Ingenito, R; Jakes, R; Middleton, D; Neill, D; Pessi, A; Wallace, A | 1 |
| Davies, R; Friedman, JH; Jacques, C | 1 |
| Factor, SA | 1 |
| Oertel, WH; Pinter, MM; Pogarell, O | 1 |
| Blasucci, L; Goetz, CG; Stebbins, GT | 1 |
| Cummings, JL | 1 |
| Bennett, JP; Piercey, MF | 1 |
| Bala, MV; Chrischilles, EA; Greer, M; Hoerger, TJ; Holloway, RG; Rowland, C | 1 |
| Fahn, S; Frucht, S; Gordon, MF; Greene, PE; Rogers, JD | 1 |
| Galiano, ML; Grandas, F | 1 |
| Hobson, DE; Martin, WR; Pourcher, E | 1 |
| Arnold, G; Kupsch, A | 1 |
| Phillips, P | 1 |
| Weiner, WJ | 1 |
| Montastruc, JL; Rascol, O; Senard, JM | 1 |
| Conway, KA; Ding, TT; Lansbury, PT; Lee, SJ; Rochet, JC; Williamson, RE | 1 |
| Lam, YW | 1 |
| Conway, KA; Harper, JD; Lansbury, PT | 1 |
| Abramova, NN; Bennett, JP; Cassarino, DS; Halvorsen, EM; Parker, WD; Sturgill, TW; Swerdlow, RH | 1 |
| Olanow, CW; Roth, T; Schapira, AH | 1 |
| Groenke, L; Mueller, D; Oechsner, M | 1 |
| Ryan, M; Slevin, JT; Wells, A | 1 |
| Clarke C, E; Clarke J, A; Speller J, M | 1 |
| Fahn, S; Frucht, SJ; Greene, PE | 1 |
| Anderson, WM; Gauger, L; Hauser, RA; Zesiewicz, TA | 1 |
| Farer, M; Hardy, J; Lee, JM; Ostrerova-Golts, N; Petrucelli, L; Wolozin, B | 1 |
| Shuster, J | 1 |
| Cassel, W; Krüger, HP; Möller, JC; Oertel, WH; Peter, JH; Stiasny, K | 1 |
| Blasucci, L; Goetz, CG; Kujawa, K; Leurgans, S; Raman, R | 1 |
| Tanner, CM | 1 |
| de Yebenes, JG | 1 |
| Hubble, JP | 1 |
| Easson, C; Farrer, M; Hardy, J; Hussey, J; Ko, L; Mehta, ND; Yen, S; Yen, SH | 1 |
| Hauser, RA; McDowell Anderson, W; Wahba, MN; Zesiewicz, TA | 1 |
| Appel, SH; Jankovic, J; Le, WD; Xie, W | 1 |
| Hebenstreit, E; Pinter, MM; Rutgers, AW | 1 |
| Earl-Slater, A; Walley, T | 1 |
| Sternon, J; Supiot, F; Zegers de Beyl, D | 1 |
| Hanna, PA; Jankovic, J; Ondo, WG; Ratkos, L | 1 |
| Agapito, C; Bhattacharya, KF; Chaudhuri, KR; Pal, S | 1 |
| Moller, H | 1 |
| Guttman, M; Houle, S; Hussey, D; Kish, S; Stewart, D; Wilson, A | 1 |
| Jankovic, J; Le, WD | 1 |
| Agid, Y; Arnulf, I; Bonnet, AM; Brefel, C; Cattelin, F; Descombes, S; Jaillon, C; Pollak, P; Rascol, O; Vidailhet, M; Xie, J | 1 |
| Ball, J | 1 |
| Diroma, C; Fraddosio, A; Iliceto, G; Lamberti, S; Moramarco, A; Palagano, G; Zenzola, A | 1 |
| Etminan, M; Rochon, PA; Samii, A; Takkouche, B | 1 |
| Biglan, KM; Holloway, RG | 1 |
| Abramova, NA; Bennett, JP; Cassarino, DS; Khan, SM; Painter, TW | 1 |
| Di Rocco, A; Tabamo, RE | 1 |
| Adler, CH; Blasucci, L; Carvey, P; Caviness, JN; Chase, WM; Ferry, JJ; Goetz, CG; Kompoliti, K; Leibowitz, MT; Leurgans, S; Pincus, JH; Raman, R; Tan, E; Yones, LC | 1 |
| Gasser, T; Meier, D; Oertel, WH; Pogarell, O; Pollentier, S; Spieker, S; van Hilten, JJ | 1 |
| Duda, JE; Giasson, BI; Golbe, LI; Lee, VM; Mabon, ME; Miller, DC; Trojanowski, JQ | 1 |
| Leissner, P; Petersén, I | 1 |
50 review(s) available for thiazoles and Parkinson Disease
| Article | Year |
|---|---|
Fyn Kinase Activity and Its Role in Neurodegenerative Disease Pathology: a Potential Universal Target?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Benzamides; Central Nervous System; Dasatinib; Humans; Molecular Targeted Therapy; Multiple Sclerosis; Myelin Sheath; Nerve Tissue Proteins; Neurodegenerative Diseases; Oligodendroglia; Parkinson Disease; Piperidines; Proto-Oncogene Proteins c-fyn; PrPC Proteins; Pyridines; Receptors, N-Methyl-D-Aspartate; T-Cell Antigen Receptor Specificity; T-Lymphocyte Subsets; tau Proteins; Thiazoles | 2021 |
Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Evidence-Based Medicine; Humans; Olanzapine; Parkinson Disease; Piperazines; Piperidines; Practice Guidelines as Topic; Psychotic Disorders; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Thiazoles; Urea | 2017 |
A Systematic Review and Case Series of Ziprasidone for Psychosis in Parkinson's Disease.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Female; Humans; Lewy Body Disease; Male; Parkinson Disease; Piperazines; Thiazoles | 2019 |
Radionuclide brain imaging correlates of cognitive impairment in Parkinson's disease (PD).
Topics: Aniline Compounds; Benzothiazoles; Brain; Brain Mapping; Cognition Disorders; Fluorodeoxyglucose F18; Humans; Parkinson Disease; Positron-Emission Tomography; Thiazoles; Tomography, Emission-Computed, Single-Photon | 2011 |
Amyloid-β and τ biomarkers in Parkinson's disease-dementia.
Topics: Amyloid beta-Peptides; Aniline Compounds; Benzothiazoles; Cerebral Cortex; Dementia; Humans; Parkinson Disease; Positron-Emission Tomography; tau Proteins; Thiazoles | 2011 |
The effects of speech therapy and pharmacological treatments on voice and speech in Parkinson s disease: a review of the literature.
Topics: Antiparkinson Agents; Benzothiazoles; Cholinergic Antagonists; Dysarthria; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease; Pramipexole; Speech; Speech Therapy; Thiazoles; Voice | 2002 |
Two advances in the management of Parkinson disease.
Topics: Age Factors; Antiparkinson Agents; Benzothiazoles; Carbidopa; Dyskinesias; Electric Stimulation Therapy; Forecasting; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Risk Factors; Stereotaxic Techniques; Thiazoles | 2002 |
DA agonists -- non-ergot derivatives: pramipexole: management of Parkinson's disease.
Topics: Benzothiazoles; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Pramipexole; Psychomotor Disorders; Randomized Controlled Trials as Topic; Thiazoles | 2002 |
[Use of dopamine agonists in the treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Controlled Clinical Trials as Topic; Dopamine Agonists; Ergolines; Humans; Indoles; Lisuride; Parkinson Disease; Pergolide; Piribedil; Placebos; Pramipexole; Serotonin Receptor Agonists; Thiazoles; Time Factors | 2002 |
Sleep attacks--facts and fiction: a critical review.
Topics: Antiparkinson Agents; Benzothiazoles; Central Nervous System Stimulants; Disorders of Excessive Somnolence; Dopamine Agonists; Humans; Indoles; Parkinson Disease; Pramipexole; Thiazoles | 2003 |
Dopamine agonists and neuroprotection in Parkinson's disease.
Topics: Animals; Antioxidants; Benzothiazoles; Disease Models, Animal; Dopamine Agonists; Environmental Exposure; Humans; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Parkinsonian Disorders; Pramipexole; Thiazoles | 2002 |
Do dopamine agonists or levodopa modify Parkinson's disease progression?
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Carrier Proteins; Dihydroxyphenylalanine; Disease Progression; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Humans; Indoles; Iodine Radioisotopes; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Parkinson Disease; Pramipexole; Radiopharmaceuticals; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tropanes | 2002 |
Dopamine agonist monotherapy in Parkinson's disease.
Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Ergolines; Humans; Indoles; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2002 |
Neuroprotection in idiopathic Parkinson's disease.
Topics: Antiparkinson Agents; Benzothiazoles; Cell Death; Dopamine Agonists; Humans; Indoles; Levodopa; Neuroprotective Agents; Parkinson Disease; Pramipexole; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2002 |
Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.
Topics: Adverse Drug Reaction Reporting Systems; Benzothiazoles; Dopamine Agonists; Humans; Indoles; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Risk Assessment; Thiazoles | 2003 |
COX-2 and neurodegeneration in Parkinson's disease.
Topics: Animals; Anti-Inflammatory Agents; Cyclooxygenase 2; Humans; Isoenzymes; Meloxicam; Membrane Proteins; Mice; MPTP Poisoning; Nerve Degeneration; Parkinson Disease; Prostaglandin-Endoperoxide Synthases; Substantia Nigra; Thiazines; Thiazoles | 2003 |
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Topics: Age of Onset; Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Evidence-Based Medicine; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2003 |
Clinical strategies to prevent and delay motor complications.
Topics: Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2003 |
[Pharmacological profiles and clinical effects of antiparkinsonian agent, pramipexole].
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Pramipexole; Thiazoles | 2004 |
Optimizing atypical antipsychotic treatment strategies in the elderly.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dementia; Dibenzothiazepines; Humans; Olanzapine; Parkinson Disease; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome | 2004 |
Sleep attacks in patients receiving dopamine-receptor agonists.
Topics: Aged; Benzothiazoles; Dopamine Agonists; Female; Humans; Indoles; Male; Middle Aged; Narcolepsy; Parkinson Disease; Pergolide; Pramipexole; Restless Legs Syndrome; Thiazoles | 2005 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
Pramipexole in the treatment of Parkinson's disease: new developments.
Topics: Antiparkinson Agents; Benzothiazoles; Depression; Expert Testimony; Humans; Parkinson Disease; Pramipexole; Product Surveillance, Postmarketing; Thiazoles; Tremor | 2005 |
Present and future drug treatment for Parkinson's disease.
Topics: Benzothiazoles; Corpus Striatum; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Humans; Indans; Indoles; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Pramipexole; Psychomotor Performance; Sexual Dysfunction, Physiological; Sleep Wake Disorders; Substantia Nigra; Thiazoles; Urinary Incontinence | 2005 |
Second generation of dopamine agonists: pros and cons.
Topics: Antiparkinson Agents; Benzothiazoles; Cabergoline; Dopamine Agonists; Drugs, Investigational; Ergolines; Humans; Indoles; Parkinson Disease; Pramipexole; Thiazoles | 1995 |
[Neurodegeneration: aging and dementia. Etiopathogenic role of electron transport disorders. Therapeutic possibilities].
Topics: Aged; Aging; Alzheimer Disease; Calcium Channel Blockers; Cerebellar Diseases; Dementia; Electron Transport; Female; Humans; Huntington Disease; Lamotrigine; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Riluzole; Thiazoles; Triazines | 1997 |
New pharmacotherapy for Parkinson's disease.
Topics: Benzophenones; Benzothiazoles; Cabergoline; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Enzyme Inhibitors; Ergolines; Humans; Indoles; Nitriles; Nitrophenols; Parkinson Disease; Pramipexole; Receptors, Dopamine D2; Thiazoles; Tolcapone | 1997 |
New options for treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Benzothiazoles; Cabergoline; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Ergolines; Guidelines as Topic; Humans; Indoles; Nitriles; Nitrophenols; Parkinson Disease; Pramipexole; Thiazoles; Tolcapone; Treatment Outcome | 1997 |
Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
Topics: Antiparkinson Agents; Benzothiazoles; Disease Progression; Dopamine Agonists; Humans; Parkinson Disease; Pramipexole; Thiazoles; Treatment Outcome | 1998 |
Do dopamine agonists provide neuroprotection?
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Clinical Trials as Topic; Dopamine Agonists; Humans; Parkinson Disease; Pramipexole; Thiazoles | 1998 |
Clinical pharmacology of dopamine agonists in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Benzothiazoles; Cabergoline; Dopamine Agonists; Ergolines; Ergot Alkaloids; Humans; Indoles; Neuroprotective Agents; Parkinson Disease; Pramipexole; Thiazoles | 1998 |
Dopamine agonists.
Topics: Apomorphine; Benzothiazoles; Bromocriptine; Dopamine Agonists; Humans; Indoles; Parkinson Disease; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Receptors, Dopamine; Thiazoles; Treatment Outcome | 1999 |
D-3 receptor agonists: combined action neurologic and neuropsychiatric agents.
Topics: Animals; Benzothiazoles; Dopamine Agonists; Humans; Mental Disorders; Nervous System Diseases; Parkinson Disease; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Thiazoles | 1999 |
Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Humans; Levodopa; Motor Activity; Parkinson Disease; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Thiazoles | 1999 |
[Pramipexol: a new dopaminergic agonist for the treatment of Parkinson disease].
Topics: Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Levodopa; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles; Treatment Outcome | 1999 |
Ropinirole and pramipexole, the new agonists.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Binding, Competitive; Clinical Trials as Topic; Dopamine Agonists; Humans; Indoles; Parkinson Disease; Pramipexole; Receptors, Dopamine; Thiazoles | 1999 |
The initial treatment of Parkinson's disease should begin with levodopa.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Drug Therapy, Combination; Essential Tremor; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine; Thiazoles; Time Factors | 1999 |
Treatment of Parkinson's disease should begin with a dopamine agonist.
Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Indoles; Levodopa; Lisuride; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D2; Thiazoles | 1999 |
Clinical pharmacology of dopamine agonists.
Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Drug Interactions; Ergolines; Humans; Indoles; Parkinson Disease; Pramipexole; Thiazoles | 2000 |
New drugs for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Benzothiazoles; Cabergoline; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Synergism; Enzyme Inhibitors; Ergolines; Humans; Indoles; Levodopa; Nitrophenols; Parkinson Disease; Pramipexole; Thiazoles; Tolcapone | 2000 |
Waking up to sleep episodes in Parkinson's disease.
Topics: Antiparkinson Agents; Automobile Driving; Benzothiazoles; Dopamine Agents; Humans; Indoles; Narcolepsy; Parkinson Disease; Pramipexole; Risk Factors; Thiazoles | 2000 |
Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Benzothiazoles; Bromocriptine; Dopamine Agonists; Drug Tolerance; Humans; Levodopa; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Thiazoles | 2000 |
["Sleep attacks" in Parkinson patients. A side effect of nonergoline dopamine agonists or a class effect of dopamine agonists?].
Topics: Accidents, Traffic; Automobile Driving; Benzothiazoles; Contraindications; Dopamine Agents; Dopamine Agonists; Germany; Humans; Indoles; Legislation, Drug; Levodopa; Narcolepsy; Parkinson Disease; Pramipexole; Thiazoles | 2000 |
Introduction: pramipexole: a novel dopamine agonist for the treatment of Parkinson's disease.
Topics: Benzothiazoles; Dopamine Agonists; Humans; Parkinson Disease; Pramipexole; Thiazoles | 2000 |
Pre-clinical studies of pramipexole: clinical relevance.
Topics: Animals; Benzothiazoles; Dopamine Agonists; Humans; Parkinson Disease; Pramipexole; Thiazoles | 2000 |
Pramipexole in the treatment of advanced Parkinson's disease.
Topics: Benzothiazoles; Clinical Trials, Phase III as Topic; Dopamine Agonists; Humans; Parkinson Disease; Pramipexole; Thiazoles | 2000 |
Digest of evidence ... pramipexole and Parkinson's disease.
Topics: Antiparkinson Agents; Benzothiazoles; Clinical Trials as Topic; Evidence-Based Medicine; Humans; Parkinson Disease; Pramipexole; Thiazoles; United Kingdom | 2000 |
Are dopamine receptor agonists neuroprotective in Parkinson's disease?
Topics: Animals; Antiparkinson Agents; Apomorphine; Benzothiazoles; Bromocriptine; Cell Culture Techniques; Clinical Trials as Topic; Dopamine Agonists; Humans; Indoles; Models, Animal; Neuroprotective Agents; Parkinson Disease; Pergolide; Pramipexole; Substantia Nigra; Thiazoles | 2001 |
Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
Topics: Antiparkinson Agents; Benzothiazoles; Disorders of Excessive Somnolence; Dopamine Agonists; Drug Therapy, Combination; Humans; Indoles; Levodopa; MEDLINE; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Risk Factors; Thiazoles | 2001 |
A review of pramipexole and its clinical utility in Parkinson's disease.
Topics: Animals; Benzothiazoles; Dopamine Agonists; Humans; Hypotension, Orthostatic; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Sleep Wake Disorders; Thiazoles; Treatment Outcome | 2002 |
39 trial(s) available for thiazoles and Parkinson Disease
| Article | Year |
|---|---|
The safety and effectiveness of mirabegron in Parkinson's disease patients with overactive bladder: a randomized controlled trial.
Topics: Acetanilides; Double-Blind Method; Humans; Parkinson Disease; Prospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2022 |
Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double-blind, randomized placebo-controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study).
Topics: Acetanilides; Aged; Double-Blind Method; Female; Humans; Male; Parkinson Disease; Surveys and Questionnaires; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2021 |
Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Benzothiazoles; Cross-Over Studies; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Surveys and Questionnaires; Thiazoles; Tremor | 2003 |
Combination of two different dopamine agonists in the management of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles; Treatment Outcome | 2002 |
Pramipexole in comparison to l-dopa: a neuropsychological study.
Topics: Aged; Analysis of Variance; Benzothiazoles; Cognition Disorders; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Pramipexole; Thiazoles | 2003 |
Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.
Topics: Activities of Daily Living; Aged; Analysis of Variance; Antiparkinson Agents; Benzothiazoles; Cross-Over Studies; Depression; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Pergolide; Placebos; Pramipexole; Prospective Studies; Psychiatric Status Rating Scales; Severity of Illness Index; Single-Blind Method; Thiazoles; Treatment Outcome | 2003 |
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Topics: Age of Onset; Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Evidence-Based Medicine; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2003 |
Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Demography; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Tolerance; Female; Humans; Male; Middle Aged; Parkinson Disease; Pramipexole; Prospective Studies; Quality of Life; Thiazoles; Time Factors; Treatment Outcome | 2003 |
Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease.
Topics: Adult; Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Female; Hong Kong; Humans; Levodopa; Male; Parkinson Disease; Pramipexole; Software Design; Taiwan; Thiazoles; Treatment Outcome | 2003 |
Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor.
Topics: Aged; Aged, 80 and over; Benzothiazoles; Dopamine Agonists; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Thiazoles; Tremor | 2003 |
Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Double-Blind Method; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Pain Measurement; Parkinson Disease; Pramipexole; Quality of Life; Thiazoles | 2004 |
[A comparative study of efficacy of dopamine receptors agonists and catechol-O-methyltransferase in the treatment of late stages of Parkinson's disease].
Topics: Activities of Daily Living; Benzophenones; Benzothiazoles; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Nitriles; Nitrophenols; Parkinson Disease; Pergolide; Pramipexole; Quality of Life; Thiazoles; Tolcapone; Treatment Outcome | 2004 |
Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
Topics: Aged; Analysis of Variance; Benzothiazoles; Dopamine Agonists; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles | 2004 |
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Topics: Aged; Benzothiazoles; Double-Blind Method; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Proportional Hazards Models; Quality of Life; Severity of Illness Index; Thiazoles | 2004 |
Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Indoles; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Pilot Projects; Pramipexole; Thiazoles | 2004 |
A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benzothiazoles; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Thiazoles; Tremor | 2005 |
Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Demography; Depression; Disorders of Excessive Somnolence; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Parkinson Disease; Pramipexole; Severity of Illness Index; Thiazoles; Tremor | 2005 |
Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease?
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Electrocardiography; Emergency Medical Services; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Parkinson Disease; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Thiazoles | 2005 |
Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole.
Topics: Activities of Daily Living; Aged; Aging; Antiparkinson Agents; Benzothiazoles; Depression; Dose-Response Relationship, Drug; Female; Humans; Male; Parkinson Disease; Pramipexole; Prospective Studies; Psychiatric Status Rating Scales; Psychomotor Performance; Thiazoles | 2005 |
Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
Topics: Administration, Oral; Adult; Antiparkinson Agents; Benzothiazoles; Cost-Benefit Analysis; Double-Blind Method; Female; Health Expenditures; Humans; Levodopa; Male; Parkinson Disease; Pramipexole; Prospective Studies; Reproducibility of Results; Sex Factors; Thiazoles; Time Factors; Treatment Outcome | 2005 |
Motor deficits in Parkinsonian reaching: dopa-sensitivity influenced by real-world task constraint.
Topics: Activities of Daily Living; Aged; Amantadine; Antiparkinson Agents; Arm; Benzothiazoles; Biomechanical Phenomena; Carbidopa; Catechols; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Movement; Nitriles; Parkinson Disease; Pramipexole; Thiazoles | 2006 |
Pramipexole in patients with early Parkinson's disease.
Topics: Adult; Benzothiazoles; Dopamine Agonists; Humans; Parkinson Disease; Pramipexole; Thiazoles; Time Factors | 1995 |
The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Female; Humans; Male; Middle Aged; Parkinson Disease; Pramipexole; Prospective Studies; Single-Blind Method; Thiazoles | 1995 |
Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Models, Statistical; Parkinson Disease; Pramipexole; Severity of Illness Index; Thiazoles | 1997 |
Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study.
Topics: Antiparkinson Agents; Benzothiazoles; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Pramipexole; Prognosis; Thiazoles | 1997 |
Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group.
Topics: Activities of Daily Living; Antiparkinson Agents; Benzothiazoles; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Parkinson Disease; Physical Examination; Placebos; Pramipexole; Severity of Illness Index; Thiazoles | 1997 |
Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Placebos; Pramipexole; Quality of Life; Severity of Illness Index; Thiazoles; Treatment Outcome | 1997 |
Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles | 1999 |
Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow?
Topics: Aged; Benzothiazoles; Dopamine Agonists; Female; Humans; Male; Middle Aged; Parkinson Disease; Pramipexole; Thiazoles; Titrimetry | 1999 |
[Pramipexol: a new dopaminergic agonist for the treatment of Parkinson disease].
Topics: Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Levodopa; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles; Treatment Outcome | 1999 |
Pramipexole-induced somnolence and episodes of daytime sleep.
Topics: Aged; Antiparkinson Agents; Automobile Driving; Benzothiazoles; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Narcolepsy; Parkinson Disease; Polysomnography; Pramipexole; Retrospective Studies; Thiazoles | 2000 |
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Topics: Antiparkinson Agents; Benzothiazoles; Carrier Proteins; Cocaine; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Double-Blind Method; Dyskinesias; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Pramipexole; Proportional Hazards Models; Quality of Life; Radiopharmaceuticals; Thiazoles; Tomography, Emission-Computed, Single-Photon | 2000 |
An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles; Treatment Outcome | 2000 |
Switching from pergolide to pramipexole in patients with Parkinson's disease.
Topics: Accidental Falls; Aged; Aged, 80 and over; Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Edema; Female; Hallucinations; Humans; Male; Middle Aged; Nausea; Parkinson Disease; Pergolide; Pramipexole; Prospective Studies; Receptors, Dopamine; Sweating; Thiazoles; Treatment Outcome | 2001 |
Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Brain Chemistry; Carbon Radioisotopes; Carrier Proteins; Cocaine; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Pramipexole; Receptors, Dopamine; Thiazoles; Tomography, Emission-Computed | 2001 |
Blockade of cholecystokinin-A receptors has no effect on dyskinesias in Parkinson's disease.
Topics: Administration, Oral; Disability Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Indoleacetic Acids; Male; Middle Aged; Movement; Parkinson Disease; Random Allocation; Receptor, Cholecystokinin A; Receptors, Cholecystokinin; Thiazoles | 2001 |
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Brain; Cocaine; Disease Progression; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Degeneration; Nerve Tissue Proteins; Parkinson Disease; Pramipexole; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Regression Analysis; Thiazoles; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2002 |
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Benzothiazoles; Biological Availability; Carbidopa; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Parkinson Disease; Postmenopause; Pramipexole; Sex Factors; Thiazoles | 2002 |
Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzothiazoles; Double-Blind Method; Drug Resistance; Electromyography; Female; Humans; Male; Middle Aged; Parkinson Disease; Placebos; Pramipexole; Thiazoles; Treatment Outcome; Tremor | 2002 |
174 other study(ies) available for thiazoles and Parkinson Disease
| Article | Year |
|---|---|
Topics: Aldehyde Dehydrogenase; Animals; Benomyl; Disease Models, Animal; Dopamine; Indoles; Parkinson Disease; Thiazoles; Zebrafish | 2022 |
Pharmacological inhibition and knockdown of O-GlcNAcase reduces cellular internalization of α-synuclein preformed fibrils.
Topics: alpha-Synuclein; Amyloid; Amyloidogenic Proteins; Animals; Antigens, Neoplasm; Antiparkinson Agents; Cell Line; Gene Expression Regulation; Glycoside Hydrolase Inhibitors; Histone Acetyltransferases; Humans; Hyaluronoglucosaminidase; Mice; Models, Biological; Neurons; Parkinson Disease; Primary Cell Culture; Protein Aggregates; Protein Transport; Pyrans; RNA, Small Interfering; Thiazoles | 2021 |
Blockade of metabotropic glutamate receptor 5 attenuates axonal degeneration in 6-hydroxydopamine-induced model of Parkinson's disease.
Topics: Animals; Axons; Calcium Signaling; Cells, Cultured; Excitatory Amino Acid Antagonists; Extracellular Signal-Regulated MAP Kinases; Female; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Piperidines; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Thiazoles | 2021 |
Pharmacological assessments of potent A
Topics: Adenosine A2 Receptor Antagonists; Adenosine-5'-(N-ethylcarboxamide); Animals; Antiparkinson Agents; Catalepsy; Female; Haloperidol; Male; Mice; Motor Activity; Parkinson Disease; Rats, Wistar; Receptor, Adenosine A2A; Thiazoles; Toxicity Tests, Acute; Toxicity Tests, Subacute; Urea | 2017 |
D-512, a novel dopamine D
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Indoles; Male; Molecular Structure; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Dopamine D3; Structure-Activity Relationship; Thiazoles | 2017 |
O-GlcNAc regulation of autophagy and α-synuclein homeostasis; implications for Parkinson's disease.
Topics: alpha-Synuclein; Animals; Autophagy; Cells, Cultured; Glucosamine; Glycosylation; Homeostasis; Humans; Models, Biological; Neurons; Parkinson Disease; Phosphorylation; Postmortem Changes; Proto-Oncogene Proteins c-akt; Pyrans; Rats, Sprague-Dawley; Signal Transduction; Sirolimus; Thiazoles; TOR Serine-Threonine Kinases | 2017 |
Deciphering the enhanced inhibitory, disaggregating and cytoprotective potential of promethazine towards amyloid fibrillation.
Topics: Amyloid; Amyloidogenic Proteins; Amyloidosis; Anilino Naphthalenesulfonates; Benzothiazoles; Circular Dichroism; Dynamic Light Scattering; Fluorescence; Humans; Insulin; Muramidase; Parkinson Disease; Promethazine; Protein Aggregates; Protein Aggregation, Pathological; Thiazoles | 2018 |
Topics: Aged; Aniline Compounds; Brain; Brain Mapping; Carbolines; Case-Control Studies; Cognition Disorders; Diagnosis; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography; Severity of Illness Index; Supranuclear Palsy, Progressive; tau Proteins; Thiazoles | 2017 |
Small molecule SUMOylation activators are novel neuroprotective agents.
Topics: Alzheimer Disease; Benzothiazoles; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Molecular Structure; Neuroprotective Agents; Parkinson Disease; Quinolines; Small Molecule Libraries; Small Ubiquitin-Related Modifier Proteins; Stroke; Structure-Activity Relationship; Sumoylation; Thiazoles | 2018 |
Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases.
Topics: Acetanilides; Aged; Central Nervous System Diseases; Dementia; Female; Humans; Male; Parkinson Disease; Stroke; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2019 |
Neuroprotective effect of IDPU (1-(7-imino-3-propyl-2,3-dihydrothiazolo [4,5-d]pyrimidin-6(7H)-yl)urea) in 6-OHDA induced rodent model of hemiparkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Depression; Disease Models, Animal; Male; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats, Wistar; Reactive Oxygen Species; Rotarod Performance Test; Thiazoles; Tyrosine 3-Monooxygenase; Urea | 2018 |
Iron Redox Chemistry Promotes Antiparallel Oligomerization of α-Synuclein.
Topics: alpha-Synuclein; Benzothiazoles; Ferrous Compounds; Fluorescent Dyes; Humans; Oxidation-Reduction; Parkinson Disease; Thiazoles | 2018 |
The correlation between striatal and cortical binding ratio of
Topics: Aged; Alzheimer Disease; Amyloid; Aniline Compounds; Cerebral Cortex; Cognitive Dysfunction; Corpus Striatum; Female; Frontotemporal Lobar Degeneration; Humans; Lewy Body Disease; Male; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Thiazoles | 2018 |
Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort.
Topics: Acetanilides; Aged; Cohort Studies; Female; Humans; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents | 2018 |
Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease.
Topics: Aged; Aged, 80 and over; Amyloid beta-Peptides; Aniline Compounds; Autopsy; Brain; Cocaine; Contrast Media; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Lewy Body Disease; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Thiazoles | 2019 |
A blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD).
Topics: alpha-Synuclein; Amyloid; Animals; Antiparkinson Agents; Benzothiazoles; Blood-Brain Barrier; Drosophila; Female; Fluorescent Dyes; Hippocampus; HSP70 Heat-Shock Proteins; Humans; Locomotion; Male; Mannitol; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Transgenic; Microscopy, Electron, Transmission; Neocortex; Parkinson Disease; Protein Multimerization; Protein Structure, Secondary; Thiazoles | 2013 |
Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
Topics: Binding Sites; Catalytic Domain; Dopamine; Humans; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxazoles; Parkinson Disease; Pyridines; Recombinant Proteins; Structure-Activity Relationship; Thiazoles | 2013 |
Different β-amyloid binding patterns in Alzheimer and Parkinson diseases: it's the network!
Topics: Alzheimer Disease; Aniline Compounds; Female; Humans; Male; Parkinson Disease; Principal Component Analysis; Radionuclide Imaging; Thiazoles | 2013 |
Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Aniline Compounds; Female; Humans; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Principal Component Analysis; Protein Binding; Thiazoles | 2013 |
D-512 and D-440 as novel multifunctional dopamine agonists: characterization of neuroprotection properties and evaluation of in vivo efficacy in a Parkinson's disease animal model.
Topics: Animals; Carotenoids; Disease Models, Animal; Dopamine Agonists; Indoles; Lycopene; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-akt; Rats; Thiazoles; Tumor Cells, Cultured | 2013 |
Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Basal Ganglia; Behavior, Animal; Benzamides; Brain; Case-Control Studies; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Parkinson Disease; Pyridines; Receptor, Serotonin, 5-HT1B; Serotonin; Sulfonamides; Thiazoles | 2013 |
Overexpression of synphilin-1 promotes clearance of soluble and misfolded alpha-synuclein without restoring the motor phenotype in aged A30P transgenic mice.
Topics: Aging; alpha-Synuclein; Animals; Autophagy; Benzothiazoles; Brain; Carrier Proteins; Gene Expression; Humans; Mice; Mice, Transgenic; Mutation; Nerve Tissue Proteins; Parkinson Disease; Protein Folding; Solubility; Thiazoles; Ubiquitin | 2014 |
Characterization of polyethylene glycol-polyethyleneimine as a vector for alpha-synuclein siRNA delivery to PC12 cells for Parkinson's disease.
Topics: alpha-Synuclein; Animals; Apoptosis; Cell Nucleus Shape; Cell Survival; Down-Regulation; Endosomes; Gene Transfer Techniques; Genetic Therapy; Intracellular Space; Neurotoxins; Parkinson Disease; Particle Size; PC12 Cells; Polyethylene Glycols; Polyethyleneimine; Rats; RNA, Messenger; RNA, Small Interfering; Tetrazolium Salts; Thiazoles | 2014 |
Structural modifications of neuroprotective anti-Parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): an effort toward the improvement of in vivo efficacy of the parent molecule.
Topics: Animals; Benzothiazoles; Biphenyl Compounds; Cell Line; Disease Models, Animal; Mice; Neuroprotective Agents; Parkinson Disease; Piperazines; Rats; Structure-Activity Relationship; Thiazoles | 2014 |
Mechanisms of dopamine D1 receptor-mediated ERK1/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Female; In Vitro Techniques; Mice; Mice, Inbred C57BL; Mice, Transgenic; Oxidopamine; Parkinson Disease; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D1; Thiazoles; Tyrosine 3-Monooxygenase | 2014 |
Extra-nigral pathological conditions are common in Parkinson's disease with freezing of gait: an in vivo positron emission tomography study.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Amyloid beta-Peptides; Aniline Compounds; Benzothiazoles; Carbon Isotopes; Cross-Sectional Studies; Female; Freezing Reaction, Cataleptic; Gait Disorders, Neurologic; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Substantia Nigra; Tetrabenazine; Thiazoles; Vesicular Monoamine Transport Proteins | 2014 |
Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
Topics: Animals; Brain; Cell Survival; Cells, Cultured; Disease Models, Animal; Guanosine Triphosphate; Humans; Inflammation; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Lipopolysaccharides; Mice; Mice, Transgenic; Microglia; Mutation; Neurons; Parkinson Disease; Phosphorylation; Protein Binding; Protein Serine-Threonine Kinases; Sulfones; Thiazoles | 2014 |
Induction of GADD45α protects M17 neuroblastoma cells against MPP*.
Topics: 1-Methyl-4-phenylpyridinium; Analysis of Variance; Anthracenes; Blotting, Western; Caspase 3; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Chromatin Immunoprecipitation; Dose-Response Relationship, Drug; Gene Expression Regulation; Humans; Imidazoles; In Situ Nick-End Labeling; Nuclear Proteins; Parkinson Disease; Pyridines; Real-Time Polymerase Chain Reaction; RNA Interference; Tetrazolium Salts; Thiazoles | 2014 |
Abberant protein synthesis in G2019S LRRK2 Drosophila Parkinson disease-related phenotypes.
Topics: Animals; Disease Models, Animal; Drosophila; Drosophila Proteins; Drug Evaluation, Preclinical; Hydrazones; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Parkinson Disease; Phenotype; Protein Biosynthesis; Protein Serine-Threonine Kinases; Ribosomal Proteins; Thiazoles | 2014 |
CSF proteins and resting-state functional connectivity in Parkinson disease.
Topics: Aged; Aged, 80 and over; alpha-Synuclein; Amyloid beta-Peptides; Aniline Compounds; Biomarkers; Brain; Brain Mapping; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Neural Pathways; Parkinson Disease; Peptide Fragments; Positron-Emission Tomography; Radiopharmaceuticals; Rest; Severity of Illness Index; Spinal Puncture; Thiazoles | 2015 |
PPARβ/δ Agonist Provides Neuroprotection by Suppression of IRE1α-Caspase-12-Mediated Endoplasmic Reticulum Stress Pathway in the Rotenone Rat Model of Parkinson's Disease.
Topics: Animals; Apoptosis; Caspase 12; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Endoplasmic Reticulum Stress; Endoribonucleases; Fluorescent Antibody Technique; Male; Motor Activity; Multienzyme Complexes; Neostriatum; Neuroprotection; Parkinson Disease; PPAR delta; PPAR-beta; Protein Serine-Threonine Kinases; Rats, Sprague-Dawley; Rotenone; Signal Transduction; Thiazoles | 2016 |
Assessment of Protective Role of Multifunctional Dopamine Agonist D-512 Against Oxidative Stress Produced by Depletion of Glutathione in PC12 Cells: Implication in Neuroprotective Therapy for Parkinson's Disease.
Topics: Animals; Caspases; Cell Survival; Dopamine Agonists; Dopaminergic Neurons; Extracellular Signal-Regulated MAP Kinases; Glutamate-Cysteine Ligase; Glutathione; Indoles; JNK Mitogen-Activated Protein Kinases; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; PC12 Cells; Rats; Signal Transduction; Thiazoles | 2015 |
Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease.
Topics: Aged; Aged, 80 and over; Amyloid beta-Peptides; Analysis of Variance; Aniline Compounds; Carbon Isotopes; Cerebral Cortex; Cognition Disorders; Corpus Striatum; Cross-Sectional Studies; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Tetrabenazine; Thiazoles | 2016 |
Expression of functional recombinant human fibroblast growth factor 8b and its protective effects on MPP⁺-lesioned PC12 cells.
Topics: Animals; Apoptosis; Baculoviridae; Cell Proliferation; Cell Survival; Chromatography, Affinity; Endoplasmic Reticulum Stress; Fibroblast Growth Factor 8; Humans; Mice; Neuroprotective Agents; NIH 3T3 Cells; Parkinson Disease; PC12 Cells; Rats; Recombinant Proteins; RNA, Messenger; Tetrazolium Salts; Thiazoles | 2016 |
Single-molecule FRET studies on alpha-synuclein oligomerization of Parkinson's disease genetically related mutants.
Topics: alpha-Synuclein; Amino Acid Sequence; Benzothiazoles; Biological Assay; Fluorescence Resonance Energy Transfer; Humans; Kinetics; Molecular Sequence Data; Mutant Proteins; Mutation, Missense; Parkinson Disease; Protein Multimerization; Thiazoles | 2015 |
PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies.
Topics: Alzheimer Disease; Aniline Compounds; Brain; Carbolines; Cocaine; Cognitive Dysfunction; Cross-Sectional Studies; Diagnosis, Differential; Lewy Body Disease; Magnetic Resonance Imaging; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Survival Analysis; Thiazoles | 2016 |
Single-Molecule Imaging of Individual Amyloid Protein Aggregates in Human Biofluids.
Topics: Aged; Aged, 80 and over; Amyloidogenic Proteins; Benzothiazoles; Circular Dichroism; Diagnostic Imaging; Female; Humans; Male; Microscopy, Atomic Force; Microscopy, Fluorescence; Middle Aged; Parkinson Disease; Thiazoles | 2016 |
Synthesis and characterization of brain penetrant prodrug of neuroprotective D-264: Potential therapeutic application in the treatment of Parkinson's disease.
Topics: Animals; Benzothiazoles; Biphenyl Compounds; Blood-Brain Barrier; Female; Hydrolysis; Male; Neuroprotective Agents; Parkinson Disease; Piperazines; Prodrugs; Rats; Rats, Sprague-Dawley; Thiazoles | 2016 |
Recurrence of dyskinesia as a side-effect of mirabegron in a patient with Parkinson's disease on DBS (GPi).
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Humans; Parkinson Disease; Recurrence; Thiazoles | 2016 |
Piceatannol and Other Wine Stilbenes: A Pool of Inhibitors against α-Synuclein Aggregation and Cytotoxicity.
Topics: alpha-Synuclein; Animals; Benzothiazoles; Cell Survival; Electrophoresis, Polyacrylamide Gel; Flavonoids; Microscopy, Electron, Transmission; Parkinson Disease; PC12 Cells; Phenols; Rats; Stilbenes; Thiazoles; Wine | 2016 |
Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.
Topics: Aged; Amyloid beta-Peptides; Aniline Compounds; Carbolines; Cognitive Dysfunction; Cross-Sectional Studies; Female; Humans; Lewy Body Disease; Magnetic Resonance Imaging; Male; Middle Aged; Neocortex; Parkinson Disease; Positron-Emission Tomography; tau Proteins; Thiazoles | 2016 |
Analysis of sheep α-synuclein provides a molecular strategy for the reduction of fibrillation.
Topics: alpha-Synuclein; Amino Acid Sequence; Amyloid; Animals; Benzothiazoles; Humans; Hydrogen-Ion Concentration; Kinetics; Lewy Bodies; Mutation; Parkinson Disease; Protein Aggregation, Pathological; Sequence Alignment; Sheep; Solubility; Thiazoles | 2017 |
Pramipexole associated dystonia.
Topics: Benzothiazoles; Dopamine Agonists; Dystonia; Dystonic Disorders; Humans; Parkinson Disease; Pramipexole; Thiazoles | 2017 |
Imaging amyloid deposition in Lewy body diseases.
Topics: Aged; Amyloid beta-Peptides; Aniline Compounds; Brain; Cognition; Dementia; Diagnosis, Differential; Female; Humans; Lewy Body Disease; Male; Middle Aged; Movement; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography; Thiazoles; Tissue Distribution | 2008 |
Neuroprotective effect of naphtha[1,2-d]thiazol-2-amine in an animal model of Parkinson's disease.
Topics: Animals; Antioxidants; Brain; Catalepsy; Disease Models, Animal; Dose-Response Relationship, Drug; Glutathione; Glutathione Peroxidase; Haloperidol; Male; Malondialdehyde; Mice; Naphthalenes; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Superoxide Dismutase; Thiazoles | 2009 |
Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation?
Topics: alpha-Synuclein; Amino Acid Sequence; Anabasine; Benzothiazoles; Chromatography, Gel; Cotinine; Humans; Hydroquinones; Microscopy, Atomic Force; Molecular Sequence Data; Mutation; Nicotine; Parkinson Disease; Protein Binding; Protein Multimerization; Smoking; Thiazoles | 2009 |
Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics.
Topics: Aged; Aged, 80 and over; Amyloid beta-Peptides; Aniline Compounds; Apolipoprotein E4; Brain; Carbon Radioisotopes; Female; Humans; Lewy Body Disease; Likelihood Functions; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Peptide Fragments; Positron-Emission Tomography; Regression Analysis; Sequence Analysis, DNA; Thiazoles | 2009 |
Dissecting the mechanisms of tissue transglutaminase-induced cross-linking of alpha-synuclein: implications for the pathogenesis of Parkinson disease.
Topics: alpha-Synuclein; Benzothiazoles; Circular Dichroism; Cross-Linking Reagents; Dimerization; Glutamine; Humans; Immunoblotting; Mutagenesis, Site-Directed; Mutation; Parkinson Disease; Protein Conformation; Spectrometry, Mass, Electrospray Ionization; Thiazoles; Transglutaminases | 2009 |
Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in vitro.
Topics: alpha-Synuclein; Benzothiazoles; Estradiol; Estriol; Gonadal Steroid Hormones; Humans; In Vitro Techniques; Lewy Bodies; Lewy Body Disease; Microscopy, Electron; Molecular Structure; Neurofibrils; Neuroprotective Agents; Parkinson Disease; Spectrometry, Fluorescence; Testosterone; Thiazoles | 2009 |
Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Free Radical Scavengers; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Isoquinolines; Locomotion; Mice; Parkinson Disease; Radioligand Assay; Rats; Receptors, Dopamine D2; Receptors, Dopamine D3; Reserpine; Structure-Activity Relationship; Thiazoles | 2010 |
In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia.
Topics: alpha-Synuclein; Amyloid; Amyloid beta-Peptides; Aniline Compounds; Autopsy; Brain Mapping; Carbon Radioisotopes; Cerebral Cortex; Dementia; Female; Humans; Lewy Bodies; Male; Mental Status Schedule; Neurofibrillary Tangles; Parkinson Disease; Positron-Emission Tomography; Prospective Studies; Protein Binding; Severity of Illness Index; tau Proteins; Thiazoles | 2010 |
DnaK/DnaJ/GrpE of Hsp70 system have differing effects on alpha-synuclein fibrillation involved in Parkinson's disease.
Topics: alpha-Synuclein; Amino Acid Sequence; Benzothiazoles; Chromatography, Gel; HSP40 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; Molecular Sequence Data; Parkinson Disease; Protein Structure, Quaternary; Thiazoles; Time Factors | 2010 |
Strategies to increase the reproducibility of protein fibrillization in plate reader assays.
Topics: alpha-Synuclein; Benzothiazoles; Fluorescent Dyes; Humans; Kinetics; Parkinson Disease; Recombinant Proteins; Reproducibility of Results; Sodium Dodecyl Sulfate; Thiazoles | 2010 |
Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease.
Topics: alpha-Synuclein; Benzothiazoles; Fetal Tissue Transplantation; Humans; Lewy Bodies; Longitudinal Studies; Male; Mesencephalon; Microscopy, Electron, Transmission; Middle Aged; Neurons; Parkinson Disease; Postmortem Changes; Thiazoles; Time Factors | 2010 |
Amyloid formation and disaggregation of α-synuclein and its tandem repeat (α-TR).
Topics: alpha-Synuclein; Amyloid; Benzothiazoles; Catechin; Flavanones; Humans; Imidazoles; Imides; Ionic Liquids; Microscopy, Electron, Transmission; Parkinson Disease; Sulfonamides; Tandem Repeat Sequences; Thiazoles | 2010 |
[(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia.
Topics: Aged; Aged, 80 and over; Aniline Compounds; Atrophy; Benzothiazoles; Cerebellum; Dementia; Female; Fluorodeoxyglucose F18; Frontal Lobe; Glucose; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Thiazoles | 2010 |
Amyloid imaging of Lewy body-associated disorders.
Topics: Aged; Aged, 80 and over; alpha-Synuclein; Amyloid beta-Peptides; Aniline Compounds; Brain; Cognition; Cognition Disorders; Diagnosis, Differential; Female; Humans; Lewy Bodies; Lewy Body Disease; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography; Severity of Illness Index; Statistics, Nonparametric; Thiazoles | 2010 |
The role of the C-terminus of human α-synuclein: intra-disulfide bonds between the C-terminus and other regions stabilize non-fibrillar monomeric isomers.
Topics: alpha-Synuclein; Benzothiazoles; Circular Dichroism; Cysteine; Cystine; Fluorescent Dyes; Humans; Isomerism; Kinetics; Mutagenesis, Site-Directed; Mutant Proteins; Oxidation-Reduction; Parkinson Disease; Protein Denaturation; Protein Folding; Protein Stability; Protein Structure, Secondary; Recombinant Proteins; Spectrometry, Fluorescence; Thiazoles | 2011 |
Mortalin inhibition in experimental Parkinson's disease.
Topics: Action Potentials; Animals; Antiparasitic Agents; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Electron Transport Complex I; Gene Expression Regulation; HSP70 Heat-Shock Proteins; In Vitro Techniques; Male; Neurons; Oxidopamine; Parkinson Disease; Proteomics; Pyridines; Rats; Rats, Wistar; Thiazoles | 2011 |
NRF2 activation restores disease related metabolic deficiencies in olfactory neurosphere-derived cells from patients with sporadic Parkinson's disease.
Topics: Case-Control Studies; Cell Line; Female; Gene Silencing; Glutathione; Humans; Isothiocyanates; Male; NF-E2-Related Factor 2; Olfactory Mucosa; Parkinson Disease; Signal Transduction; Sulfoxides; Tetrazolium Salts; Thiazoles; Thiocyanates | 2011 |
Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.
Topics: Binding Sites; Humans; Hydrazones; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Dynamics Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Protein Conformation; Structure-Activity Relationship; Tandem Mass Spectrometry; Thiazoles | 2012 |
Isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors: SAR and pharmacokinetic evaluation.
Topics: Central Nervous System; Cyclic Nucleotide Phosphodiesterases, Type 7; Humans; Isoxazoles; Parkinson Disease; Pharmacokinetics; Phosphodiesterase Inhibitors; Pyrimidinones; Structure-Activity Relationship; Thiazoles | 2012 |
Detection of α-synuclein aggregates by fluorescence microscopy.
Topics: alpha-Synuclein; Benzothiazoles; Biomarkers; Circular Dichroism; Dopaminergic Neurons; Fluorescent Dyes; Humans; Hydrogen-Ion Concentration; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Models, Biological; Neurodegenerative Diseases; Parkinson Disease; Recombinant Proteins; Surface Properties; Temperature; Thiazoles | 2012 |
Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Hypokinesia; Male; Meloxicam; Mesencephalon; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Thiazines; Thiazoles; Tyrosine 3-Monooxygenase | 2012 |
Brain amyloid and cognition in Lewy body diseases.
Topics: Aged; Amyloid beta-Peptides; Aniline Compounds; Antiparkinson Agents; Apolipoprotein E3; Cognition; Cognitive Dysfunction; Female; Genotype; Humans; Levodopa; Lewy Body Disease; Male; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography; Thiazoles | 2012 |
Characterization of semisynthetic and naturally Nα-acetylated α-synuclein in vitro and in intact cells: implications for aggregation and cellular properties of α-synuclein.
Topics: Acetylation; alpha-Synuclein; Animals; Benzothiazoles; Escherichia coli; HEK293 Cells; HeLa Cells; Humans; Mice; Mice, Knockout; Multiprotein Complexes; Parkinson Disease; Protein Binding; Protein Structure, Secondary; Saccharomyces cerevisiae; Thiazoles | 2012 |
Ubiquitin proteasome system in Parkinson's disease: a keeper or a witness?
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Case-Control Studies; Cell Line, Tumor; Cell Proliferation; Chymotrypsin; Citrate (si)-Synthase; Electron Transport Complex I; Female; Green Fluorescent Proteins; Humans; Immunoprecipitation; Lactic Acid; Leukocytes, Mononuclear; Male; Middle Aged; Mitochondria; Neuroblastoma; Parkinson Disease; Plasma; Proteasome Endopeptidase Complex; RNA, Small Interfering; Statistics as Topic; Tetrazolium Salts; Thiazoles; Transfection; Ubiquitin; Ubiquitination; Up-Regulation | 2012 |
β-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy.
Topics: Aged; Aging; Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Aniline Compounds; Atrophy; Benzothiazoles; Dementia; Female; Humans; Image Processing, Computer-Assisted; Lewy Body Disease; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Thiazoles | 2013 |
β-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia.
Topics: Aged; Aged, 80 and over; Amyloid beta-Peptides; Aniline Compounds; Carbon Isotopes; Cross-Sectional Studies; Dementia; Female; Gait Disorders, Neurologic; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Postural Balance; Psychiatric Status Rating Scales; Sensation Disorders; Severity of Illness Index; Tetrabenazine; Thiazoles | 2013 |
Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia.
Topics: Aged; Amyloid; Aniline Compounds; Apolipoprotein E4; Biomarkers; Carbon Radioisotopes; Cognitive Dysfunction; Dementia; Disease Progression; Female; Functional Neuroimaging; Humans; Male; Neuropsychological Tests; Parietal Lobe; Parkinson Disease; Positron-Emission Tomography; Prospective Studies; Thiazoles | 2013 |
IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antioxidants; Antiparkinson Agents; Behavior, Animal; Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Disease Models, Animal; Dopamine Agents; Dyskinesias; Immunohistochemistry; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Neurons; Oxidative Stress; Parkinson Disease; Positron-Emission Tomography; Thiazoles | 2013 |
Simultaneous measurement of amyloid fibril formation by dynamic light scattering and fluorescence reveals complex aggregation kinetics.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid; Amyloid beta-Peptides; Benzothiazoles; Fluorescence; Humans; Huntington Disease; Kinetics; Light; Parkinson Disease; Particle Size; Protein Structure, Secondary; Thiazoles | 2013 |
Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies.
Topics: alpha-Synuclein; Analysis of Variance; Benzothiazoles; Blotting, Western; Carrier Proteins; Chromatography, Reverse-Phase; DNA Primers; Humans; Inflammasomes; Inflammation; Interleukin-1beta; Lewy Bodies; Microscopy, Atomic Force; Microscopy, Confocal; Microscopy, Electron, Transmission; Neurons; NLR Family, Pyrin Domain-Containing 3 Protein; Parkinson Disease; Phagocytosis; Real-Time Polymerase Chain Reaction; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Thiazoles; Toll-Like Receptor 2 | 2013 |
Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease.
Topics: Antiparkinson Agents; Benzothiazoles; Brain; Cocaine; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Humans; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Parkinson Disease; Pramipexole; Radiopharmaceuticals; Thiazoles; Tomography, Emission-Computed, Single-Photon | 2002 |
[Pramipexole in Parkinson disease. Results of a treatment observation].
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Clinical Trials as Topic; Dopamine Agonists; Female; Humans; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pramipexole; Product Surveillance, Postmarketing; Receptors, Dopamine D2; Thiazoles; Treatment Outcome | 2002 |
Motor effects of a dopamine stabilizer (GMC1111) in primate models of Parkinson and hemiparkinsonism.
Topics: Animals; Callithrix; Disease Models, Animal; Dopamine; Dyskinesias; Female; Indans; Male; Motor Activity; Oxidopamine; Parkinson Disease; Prosencephalon; Thiazoles | 2003 |
Loss of color vision during long-term treatment with pramipexole.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Color Vision Defects; Humans; Male; Parkinson Disease; Pramipexole; Thiazoles; Time Factors | 2003 |
[(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease.
Topics: Antiparkinson Agents; Benzothiazoles; Caudate Nucleus; Cocaine; Corpus Striatum; Disease Progression; Female; Humans; Male; Nerve Degeneration; Parkinson Disease; Pergolide; Pramipexole; Putamen; Radiopharmaceuticals; Receptors, Dopamine D2; Reproducibility of Results; Thiazoles; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2003 |
The initial drug treatment of older patients with Parkinson's disease - consider an agonist, but don't demonise dopa.
Topics: Antiparkinson Agents; Benzothiazoles; Catechol O-Methyltransferase; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Indoles; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Thiazoles | 2003 |
REAL and CALM: what have we learned?
Topics: Antiparkinson Agents; Benzothiazoles; Clinical Trials as Topic; Corpus Striatum; Disease Progression; Dopamine; Feasibility Studies; Humans; Indoles; Levodopa; Neurons; Neuroprotective Agents; Parkinson Disease; Pramipexole; Putamen; Reference Values; Sensitivity and Specificity; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2003 |
Pathological gambling associated with dopamine agonist therapy in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Female; Gambling; Humans; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Recurrence; Retrospective Studies; Suicide; Thiazoles | 2003 |
Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration.
Topics: Animals; Benzothiazoles; Corpus Striatum; Dopamine; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Degeneration; Neuropeptides; Parkinson Disease; Pramipexole; Rats; Rats, Sprague-Dawley; Synaptic Vesicles; Thiazoles; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2003 |
Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease.
Topics: Activities of Daily Living; Aged; Benzothiazoles; Clinical Trials, Phase III as Topic; Female; Humans; Male; Middle Aged; Muscle Rigidity; Observation; Parkinson Disease; Pramipexole; Prospective Studies; Statistics, Nonparametric; Thiazoles | 2003 |
Oral anticoagulation for ECG tremor artefact simulating atrial fibrillation.
Topics: Aged; Anticoagulants; Antiparkinson Agents; Atrial Fibrillation; Benzothiazoles; Diagnosis, Differential; Diagnostic Errors; Electrocardiography; Female; Humans; Parkinson Disease; Phenprocoumon; Pramipexole; Thiazoles | 2003 |
Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
Topics: Aged; Benzothiazoles; Bromocriptine; Disorders of Excessive Somnolence; Dopamine Agonists; Dose-Response Relationship, Drug; Ergot Alkaloids; Female; Humans; Indoles; Male; Middle Aged; Parkinson Disease; Pergolide; Polysomnography; Pramipexole; Prospective Studies; Sleep; Thiazoles; Wakefulness | 2004 |
Slowing Parkinson's disease progression: recent dopamine agonist trials.
Topics: Antiparkinson Agents; Artifacts; Benzothiazoles; Clinical Trials as Topic; Disease Progression; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Pramipexole; Severity of Illness Index; Single-Blind Method; Thiazoles | 2004 |
Slowing Parkinson's disease progression: recent dopamine agonist trials.
Topics: Antiparkinson Agents; Benzothiazoles; Biological Transport; Cell Line, Tumor; Clinical Trials as Topic; Dopamine; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Humans; In Vitro Techniques; Indoles; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Neuroblastoma; Parkinson Disease; Pramipexole; Thiazoles | 2004 |
Ziprasidone in Parkinson's disease psychosis.
Topics: Aged; Antipsychotic Agents; Dopamine Agonists; Humans; Levodopa; Male; Parkinson Disease; Piperazines; Psychoses, Substance-Induced; Thiazoles | 2004 |
Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge.
Topics: Antipsychotic Agents; Female; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Piperazines; Thiazoles | 2004 |
NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation.
Topics: alpha-Synuclein; Amino Acid Sequence; Benzothiazoles; Binding Sites; Fluorescent Dyes; Humans; Molecular Sequence Data; Molecular Structure; Nerve Tissue Proteins; Nuclear Magnetic Resonance, Biomolecular; Parkinson Disease; Polyamines; Protein Structure, Secondary; Synucleins; Thiazoles | 2004 |
Pramipexole-treated Parkinson's disease during pregnancy.
Topics: Adult; Benzothiazoles; Dopamine Agonists; Female; Humans; Parkinson Disease; Pramipexole; Pregnancy; Pregnancy Complications; Severity of Illness Index; Thiazoles | 2004 |
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Therapeutic Equivalency; Thiazoles | 2004 |
Predictors of sudden onset of sleep in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Comorbidity; Cross-Sectional Studies; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Narcolepsy; Parkinson Disease; Pramipexole; Risk Factors; Surveys and Questionnaires; Thiazoles | 2004 |
Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Down-Regulation; Injections, Subcutaneous; Mice; Mice, Inbred C57BL; Mice, Knockout; Nerve Fibers; Neurons; Neuroprotective Agents; Parkinson Disease; Pramipexole; Receptors, Dopamine D3; Thiazoles | 2004 |
Pro-apoptotic protein glyceraldehyde-3-phosphate dehydrogenase promotes the formation of Lewy body-like inclusions.
Topics: Acetates; Aged; Aged, 80 and over; alpha-Synuclein; Animals; beta-Synuclein; Blotting, Western; Brain; Cell Aggregation; Cell Count; Chlorocebus aethiops; COS Cells; Female; Gene Expression Regulation; Glyceraldehyde-3-Phosphate Dehydrogenases; Green Fluorescent Proteins; Humans; Immunohistochemistry; Immunoprecipitation; Inclusion Bodies; Indoles; Lewy Bodies; Male; Microscopy, Electron, Transmission; Middle Aged; Mutagenesis, Site-Directed; Nerve Tissue Proteins; Parkinson Disease; Polymerase Chain Reaction; Synucleins; Thiazoles; Transfection; Ubiquitin | 2005 |
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease.
Topics: Aged; Amantadine; Benzothiazoles; Catechols; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Humans; Iatrogenic Disease; Indoles; Levodopa; Male; Middle Aged; Neurology; Neuropharmacology; Neurotoxicity Syndromes; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles; Treatment Outcome | 2005 |
Tyrosinase exacerbates dopamine toxicity but is not genetically associated with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Animals; Blotting, Northern; Blotting, Western; Brain; Cell Count; Cells, Cultured; Cloning, Molecular; Dopamine; Drug Interactions; Female; Fluorescent Antibody Technique; Gene Frequency; Genotype; Haplotypes; Humans; Immunoprecipitation; Male; Mice; Middle Aged; Monophenol Monooxygenase; Neuroblastoma; Neurons; Parkinson Disease; Polymorphism, Genetic; Postmortem Changes; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazolium Salts; Thiazoles; Time Factors; Transduction, Genetic; Transfection | 2005 |
Pramipexole, ropinirole, and mania in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Benzothiazoles; Bipolar Disorder; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2005 |
Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases.
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blotting, Western; Catalytic Domain; Cell Line, Tumor; Cell Survival; Coloring Agents; Culture Media; Dopamine; Humans; Immunohistochemistry; Insecta; Kinetics; Male; Matrix Metalloproteinase 3; Matrix Metalloproteinases; Nerve Tissue Proteins; Nitric Oxide; Nitrites; Oxidopamine; Oxygen; Parkinson Disease; Protein Binding; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Substantia Nigra; Synucleins; Tetrazolium Salts; Thiazoles; Time Factors; Transfection | 2005 |
Isatin, an endogenous monoamine oxidase inhibitor, triggers a dose- and time-dependent switch from apoptosis to necrosis in human neuroblastoma cells.
Topics: Annexin A5; Antiparkinson Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Cell Survival; Dopamine; Dose-Response Relationship, Drug; Energy Metabolism; Humans; Isatin; Monoamine Oxidase Inhibitors; Necrosis; Neuroblastoma; Neurons; Neurotoxins; Parkinson Disease; Propidium; Tetrazolium Salts; Thiazoles; Time Factors | 2005 |
Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway.
Topics: alpha-Synuclein; Amyloid; Benzothiazoles; Circular Dichroism; Dopamine; Ferric Compounds; Humans; Parkinson Disease; Protein Folding; Protein Structure, Secondary; Sodium Dodecyl Sulfate; Thiazoles | 2005 |
Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antiparkinson Agents; Benzoquinones; Benzothiazoles; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Electron Spin Resonance Spectroscopy; Functional Laterality; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine; Parkinson Disease; Pramipexole; Thiazoles; Time Factors | 2005 |
Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra.
Topics: Aging; Alkaloids; alpha-Synuclein; Animals; Axons; Benzothiazoles; Brain-Derived Neurotrophic Factor; Crosses, Genetic; Densitometry; Dopamine; Fluorescent Dyes; Heterozygote; Immunohistochemistry; Indoles; Ligands; Male; Mice; Mutation; Neurons; Parkinson Disease; Phenotype; Quinolines; Receptor, trkB; Receptor, trkC; Signal Transduction; Substantia Nigra; Thiazoles; Tyrosine 3-Monooxygenase | 2005 |
Protective effect of green tea polyphenols on the SH-SY5Y cells against 6-OHDA induced apoptosis through ROS-NO pathway.
Topics: Annexin A5; Apoptosis; Blotting, Western; Calcium; Cell Line, Tumor; Cell Survival; Coloring Agents; Dose-Response Relationship, Drug; Flavonoids; Flow Cytometry; Free Radicals; Guanosine Triphosphate; Humans; Membrane Potentials; Mitochondria; Models, Biological; Neurons; Nitric Oxide; Oxidopamine; Oxygen; Parkinson Disease; Phenols; Polyphenols; Quinones; Reactive Oxygen Species; Tea; Tetrazolium Salts; Thiazoles; Time Factors; Tyrosine | 2005 |
Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Drug Administration Schedule; Humans; Lung; Male; Molecular Structure; Parkinson Disease; Pergolide; Pleura; Pleural Diseases; Pramipexole; Pulmonary Fibrosis; Thiazoles; Tomography, X-Ray Computed | 2005 |
Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.
Topics: Animals; Benzothiazoles; Binding, Competitive; Brain; Cells, Cultured; Cricetinae; Domperidone; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Humans; Mice; Neurons; Oxazines; Parkinson Disease; Pramipexole; Radioligand Assay; Rats; Receptors, Dopamine D2; Receptors, Dopamine D3; Synapses; Synaptic Transmission; Thiazoles; Tritium | 2005 |
Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Catechols; Databases, Factual; Dopamine Agonists; Humans; Indoles; Levodopa; Male; Mental Disorders; Middle Aged; Multiple System Atrophy; Nitriles; Parkinson Disease; Pramipexole; Sexual Dysfunctions, Psychological; Thiazoles | 2005 |
[Syndrome of inappropriate ADH secretion (SIADH) induced by pramipexole in a patient with Parkinson's disease].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benzothiazoles; Female; Humans; Parkinson Disease; Pituitary ACTH Hypersecretion; Pramipexole; Thiazoles | 2005 |
Ziprasidone in the treatment of Parkinson's disease psychosis.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Motor Activity; Parkinson Disease; Piperazines; Psychotic Disorders; Taiwan; Thiazoles; Treatment Outcome | 2006 |
Amyloid fibril formation of alpha-synuclein is accelerated by preformed amyloid seeds of other proteins: implications for the mechanism of transmissible conformational diseases.
Topics: alpha-Synuclein; Amyloid; Animals; Benzothiazoles; Biochemistry; Cattle; Chaperonin 10; Chickens; Circular Dichroism; Escherichia coli; Humans; Insulin; Lewy Bodies; Microscopy, Atomic Force; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Models, Biological; Molecular Chaperones; Muramidase; Parkinson Disease; Peptides; Protein Binding; Protein Conformation; Scattering, Radiation; Thiazoles; X-Rays | 2005 |
Pathological gambling in Parkinson's disease.
Topics: Antiparkinson Agents; Benzothiazoles; Brain; Dopamine Agonists; Dose-Response Relationship, Drug; Gambling; Humans; Indoles; Mental Disorders; Neural Pathways; Parkinson Disease; Pramipexole; Thiazoles | 2005 |
Characterization of oligomeric intermediates in alpha-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F alpha-synuclein.
Topics: alpha-Synuclein; Anilino Naphthalenesulfonates; Benzothiazoles; Fluorescence Resonance Energy Transfer; Fluorescent Dyes; Humans; Mutagenesis, Site-Directed; Nerve Tissue Proteins; Parkinson Disease; Protein Structure, Secondary; Spectroscopy, Fourier Transform Infrared; Synucleins; Thiazoles; Tryptophan; Tyrosine | 2005 |
Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans.
Topics: 3-Hydroxybutyric Acid; alpha-Synuclein; Amino Acid Sequence; Animals; Animals, Genetically Modified; Antioxidants; Apoptosis; Benzoates; Benzothiazoles; Bile Acids and Salts; Caenorhabditis elegans; Cholagogues and Choleretics; Copper; Disease Models, Animal; Electron Transport Complex I; Gene Deletion; Gene Expression Regulation; Gene Library; Genetic Techniques; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Ions; Iron; Mitochondria; Molecular Sequence Data; Mutagenesis; Mutation; Neurons; Oncogene Proteins; Oxygen Consumption; Paraquat; Parkinson Disease; Polyenes; Probucol; Protein Deglycase DJ-1; Pyrazoles; Pyridazines; RNA, Small Interfering; Rotenone; Sequence Homology, Amino Acid; Sodium Azide; Taurochenodeoxycholic Acid; Thiazoles; Time Factors; Transgenes; Ubiquitin-Protein Ligases | 2005 |
1-methyl-4-phenylpyridinium neurotoxicity is attenuated by adenoviral gene transfer of human Cu/Zn superoxide dismutase.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cell Count; Cell Line, Tumor; Disease Models, Animal; Female; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Immunohistochemistry; Motor Activity; Neuroblastoma; Neurotoxicity Syndromes; Parkinson Disease; Rats; Rotarod Performance Test; Substantia Nigra; Superoxide Dismutase; Tetrazolium Salts; Thiazoles; Transgenes; Tyrosine 3-Monooxygenase | 2006 |
Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase.
Topics: Aged; Aged, 80 and over; Astrocytes; Case-Control Studies; Cell Survival; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Glial Fibrillary Acidic Protein; Glutathione Peroxidase; Humans; Immunohistochemistry; Male; Nerve Growth Factors; Neurons; Parkinson Disease; Prothrombin; Receptor, PAR-1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazolium Salts; Thiazoles; Thrombin; Time Factors; Up-Regulation | 2006 |
Gambling and Parkinson disease.
Topics: Antiparkinson Agents; Benzothiazoles; Gambling; Humans; Levodopa; Parkinson Disease; Pramipexole; Risk Factors; Thiazoles | 2006 |
Hiccups associated with dopamine agonists in Parkinson disease.
Topics: Aged; Benzothiazoles; Dopamine Agonists; Hiccup; Humans; Male; Parkinson Disease; Pergolide; Pramipexole; Thiazoles | 2006 |
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesias; Functional Laterality; Haloperidol; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Pyridines; Quinolines; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Rotarod Performance Test; Thiazoles; Time Factors | 2006 |
Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage.
Topics: alpha-Synuclein; Benzothiazoles; Cell Differentiation; Cell Line, Tumor; Cytoplasm; Ferrous Compounds; Humans; Immunohistochemistry; Molsidomine; Mutation; Neuroblastoma; Oxidative Stress; Parkinson Disease; Proteasome Inhibitors; Reactive Oxygen Species; Rotenone; Thiazoles; Ubiquitin | 2006 |
Chronic cluster headache responsive to pramipexole.
Topics: Antiparkinson Agents; Benzothiazoles; Cluster Headache; Dopamine Agonists; Humans; Incidental Findings; Male; Middle Aged; Parkinson Disease; Pramipexole; Thiazoles; Treatment Outcome | 2006 |
Reversal learning in Parkinson's disease depends on medication status and outcome valence.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Benzothiazoles; Case-Control Studies; Female; Humans; Learning Disabilities; Male; Middle Aged; Neuropsychological Tests; Outcome Assessment, Health Care; Parkinson Disease; Pramipexole; Reversal Learning; Thiazoles | 2006 |
Association of dopamine agonist use with impulse control disorders in Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Benzothiazoles; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Follow-Up Studies; Gambling; Humans; Indoles; Logistic Models; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Risk Factors; Sexual Behavior; Sexual Dysfunction, Physiological; Thiazoles | 2006 |
[Dopamine receptors agonists (mirapex) in the treatment of Parkinson's disease].
Topics: Anxiety; Benzothiazoles; Carbidopa; Delayed-Action Preparations; Depression; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Receptors, Dopamine D1; Thiazoles; Treatment Outcome | 2006 |
Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Laughter; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Piperazines; Psychoses, Substance-Induced; Quetiapine Fumarate; Thiazoles | 2007 |
Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo.
Topics: Acetates; Animals; Brain; Brain Ischemia; Caspases; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dopamine; Genes, Reporter; Humans; Ligands; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease; Phenols; Phenoxyacetates; PPAR delta; Rats; Rats, Wistar; Substrate Specificity; Thiazoles | 2007 |
Vitamin A potently destabilizes preformed alpha-synuclein fibrils in vitro: implications for Lewy body diseases.
Topics: alpha-Synuclein; Antioxidants; Benzothiazoles; beta Carotene; Coenzymes; Humans; Lewy Body Disease; Microscopy, Atomic Force; Microscopy, Electron; Microscopy, Fluorescence; Neurofibrils; Neuroprotective Agents; Parkinson Disease; Thiazoles; Ubiquinone; Vitamin A; Vitamins | 2007 |
[(11)C]-PIB imaging in patients with Parkinson's disease: preliminary results.
Topics: Aged; Aniline Compounds; Benzothiazoles; Brain Mapping; Female; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Thiazoles | 2008 |
Ziprasidone for drug-induced psychotic symptoms in Parkinson's Disease.
Topics: Acute Disease; Antipsychotic Agents; Brief Psychiatric Rating Scale; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Psychoses, Substance-Induced; Thiazoles | 2008 |
[11C]PIB binding in Parkinson's disease dementia.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Aniline Compounds; Brain; Dementia; Diagnosis, Differential; Female; Humans; Lewy Body Disease; Male; Melanins; Microscopy, Fluorescence; Middle Aged; Neuropsychological Tests; Parkinson Disease; Protein Structure, Secondary; Radionuclide Imaging; Radiopharmaceuticals; Thiazoles | 2008 |
Apoptotic death induces Abeta production and fibril formation to a much larger extent than necrotic-like death in CGNs.
Topics: Aged; Alzheimer Disease; Amyloid beta-Protein Precursor; Apoptosis; Benzothiazoles; Cerebellum; DNA Fragmentation; Enzyme-Linked Immunosorbent Assay; Fluorescent Dyes; Humans; Huntington Disease; Membrane Proteins; Microfilament Proteins; Microscopy, Electron, Transmission; Necrosis; Parkinson Disease; Reticulin; Thiazoles | 2007 |
Effects of the extract of Anemopaegma mirandum (Catuaba) on Rotenone-induced apoptosis in human neuroblastomas SH-SY5Y cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Shape; Cell Survival; Cytoprotection; DNA Fragmentation; Dose-Response Relationship, Drug; Humans; Intracellular Membranes; Microscopy, Electron, Transmission; Nerve Degeneration; Neurons; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Plant Extracts; Rotenone; Tetrazolium Salts; Thiazoles | 2008 |
Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers.
Topics: alpha-Synuclein; Benzothiazoles; Electrophysiology; Flavanones; Fluorescent Dyes; Gene Expression Regulation; Humans; Iron; Lipid Bilayers; Microscopy, Atomic Force; Microscopy, Confocal; Models, Biological; Parkinson Disease; Protein Binding; Solvents; Thiazoles | 2008 |
Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell cultures.
Topics: Amphetamine; Animals; Antioxidants; Apomorphine; Behavior, Animal; Cell Line, Tumor; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Humans; L-Lactate Dehydrogenase; Male; Motor Activity; Neuroblastoma; Oxidopamine; Parkinson Disease; Quercetin; Rats; Rats, Wistar; Substantia Nigra; Tetrazolium Salts; Thiazoles; Tyrosine 3-Monooxygenase | 2008 |
Endogenous dopamine (DA) renders dopaminergic cells vulnerable to challenge of proteasome inhibitor MG132.
Topics: alpha-Methyltyrosine; Animals; Cell Survival; Cysteine Proteinase Inhibitors; Dopamine; Leupeptins; Malondialdehyde; Mice; Neurodegenerative Diseases; Neurons; Parkinson Disease; PC12 Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Rats; Tetrazolium Salts; Thiazoles | 2008 |
Rat brain binding sites for pramipexole, a clinically useful D3-preferring dopamine agonist.
Topics: Animals; Autoradiography; Benzothiazoles; Binding Sites; Brain; Cloning, Molecular; Dopamine Agonists; Male; Parkinson Disease; Pramipexole; Rats; Rats, Sprague-Dawley; Schizophrenia; Tetrahydronaphthalenes; Thiazoles | 1995 |
Dendritic reorganisation in the basal forebrain under degenerative conditions and its defects in Alzheimer's disease. II. Ageing, Korsakoff's disease, Parkinson's disease, and Alzheimer's disease.
Topics: Adult; Aged; Aging; Alcohol Amnestic Disorder; Alzheimer Disease; Benzothiazoles; Cell Count; Dendrites; Female; Fluorescent Dyes; Histocytochemistry; Humans; Male; Middle Aged; Nerve Degeneration; Neuronal Plasticity; Parkinson Disease; Prosencephalon; Staining and Labeling; Thiazoles | 1995 |
Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons--a possible novel pathogenetic mechanism in Parkinson's disease.
Topics: Animals; Apoptosis; Cell Nucleus; Cells, Cultured; Chick Embryo; Coloring Agents; DNA Damage; Dopamine; Flow Cytometry; Neurons; Parkinson Disease; Sympathetic Nervous System; Tetrazolium Salts; Thiazoles | 1994 |
Neurofibrillary tangles in the dentate granule cells of patients with Alzheimer's disease, Lewy body disease and progressive supranuclear palsy.
Topics: Alzheimer Disease; Antibodies, Monoclonal; Benzothiazoles; Dentate Gyrus; Fluorescent Dyes; Humans; Immunohistochemistry; Microscopy, Immunoelectron; Neurofibrillary Tangles; Parkinson Disease; Supranuclear Palsy, Progressive; Thiazoles | 1997 |
New dopamine agonists on the horizon.
Topics: Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Humans; Indoles; Parkinson Disease; Pramipexole; Thiazoles | 1997 |
Pramipexole marketed for Parkinson's disease.
Topics: Antiparkinson Agents; Benzothiazoles; Drug Approval; Humans; Parkinson Disease; Pramipexole; Thiazoles; United States; United States Food and Drug Administration | 1997 |
Pramipexole and ropinirole for Parkinson's disease.
Topics: Antiparkinson Agents; Benzothiazoles; Clinical Trials as Topic; Dopamine Agonists; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Humans; Indoles; Parkinson Disease; Pramipexole; Thiazoles | 1997 |
Pramipexole for Parkinson's disease.
Topics: Adult; Benzothiazoles; Dopamine Agonists; Double-Blind Method; Humans; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Reproducibility of Results; Thiazoles; Treatment Outcome | 1998 |
Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease.
Topics: Benzothiazoles; Humans; Hydrogen-Ion Concentration; Nerve Tissue Proteins; Osmolar Concentration; Parkinson Disease; Recombinant Proteins; Synucleins; Temperature; Thiazoles; Time Factors | 1998 |
New anti-parkinsonian drugs.
Topics: Antiparkinson Agents; Benzophenones; Benzothiazoles; Humans; Indoles; Levodopa; Nitrophenols; Parkinson Disease; Pramipexole; Thiazoles; Tolcapone | 1998 |
Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease.
Topics: alpha-Synuclein; Amino Acid Substitution; Amyloid; Benzothiazoles; Biopolymers; Circular Dichroism; Dimerization; Humans; Hydrogen-Ion Concentration; Lewy Bodies; Microscopy, Electron; Mutation; Nerve Tissue Proteins; Parkinson Disease; Protein Structure, Secondary; Recombinant Proteins; Synucleins; Thiazoles | 1998 |
Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments.
Topics: alpha-Synuclein; Amyloid; Apoptosis; Benzothiazoles; Biopolymers; Cell Nucleus; Cell Survival; Circular Dichroism; Humans; Microscopy, Electron; Mutation; Nerve Tissue Proteins; Neuroblastoma; Neurodegenerative Diseases; Neurons; Parkinson Disease; Peptides; Protein Structure, Secondary; Synucleins; Thiazoles; Tumor Cells, Cultured | 1998 |
Weight loss is often a problem in late PD.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benzothiazoles; Drug Monitoring; Female; Humans; Male; Middle Aged; Parkinson Disease; Pramipexole; Thiazoles; Weight Gain | 1998 |
Cost effectiveness of pramipexole in Parkinson's disease in the US.
Topics: Antiparkinson Agents; Benzothiazoles; Cost-Benefit Analysis; Humans; Parkinson Disease; Pramipexole; Quality-Adjusted Life Years; Sensitivity and Specificity; Thiazoles; United States | 1998 |
Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Automobile Driving; Benzothiazoles; Humans; Indoles; Male; Middle Aged; Parkinson Disease; Pramipexole; Sleep; Thiazoles; Wakefulness | 1999 |
[High dosage therapy of Parkinson disease. New dopamine agonist pramipexol allows reduction of L-dopa dose down to zero].
Topics: Antiparkinson Agents; Benzothiazoles; Carbidopa; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pramipexole; Thiazoles | 1999 |
Several classes of new drugs emerging for Parkinson disease.
Topics: Antiparkinson Agents; Benzothiazoles; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Enzyme Inhibitors; Humans; Indoles; Levodopa; Nitriles; Parkinson Disease; Pramipexole; Thiazoles | 1999 |
Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.
Topics: Age of Onset; alpha-Synuclein; Amino Acid Substitution; Amyloid; Benzothiazoles; Chromatography, Gel; Circular Dichroism; Fluorescence; Humans; Microscopy, Atomic Force; Mutation; Nerve Tissue Proteins; Parkinson Disease; Protein Conformation; Synucleins; Thiazoles; Ultracentrifugation | 2000 |
Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
Topics: Alanine; alpha-Synuclein; Amino Acid Sequence; Amyloid; Benzothiazoles; Binding Sites; Brain; Circular Dichroism; Congo Red; Endopeptidases; Humans; Hydrolysis; Immunohistochemistry; Lewy Bodies; Microscopy, Atomic Force; Microscopy, Polarization; Molecular Sequence Data; Mutation, Missense; Nerve Tissue Proteins; Parkinson Disease; Postmortem Changes; Proline; Protein Structure, Secondary; Recombinant Proteins; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared; Synucleins; Thiazoles; Threonine | 2000 |
Interaction among mitochondria, mitogen-activated protein kinases, and nuclear factor-kappaB in cellular models of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Adenine Nucleotides; Benzothiazoles; Electron Transport; Enzyme Activation; Free Radical Scavengers; Herbicides; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase Kinase 1; Mitochondria; Mitogen-Activated Protein Kinases; Neuroblastoma; Neurons; NF-kappa B; Oxidative Stress; Parkinson Disease; Peptides; Pramipexole; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-raf; Signal Transduction; Superoxide Dismutase; Thiazoles; Tumor Cells, Cultured | 2000 |
Pleural fibrosis associated with dihydroergocryptine treatment.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cough; Dopamine Agonists; Dyspnea; Ergolines; Humans; Male; Parkinson Disease; Pramipexole; Pulmonary Fibrosis; Thiazoles | 2000 |
Non-ergot dopamine agonist-induced sleep attacks.
Topics: Aged; Benzothiazoles; Dopamine Agonists; Female; Humans; Indoles; Male; Middle Aged; Parkinson Disease; Pramipexole; Sleep Wake Disorders; Thiazoles | 2000 |
Sleep episodes in Parkinson's disease: a wake-up call.
Topics: Accidents, Traffic; Antiparkinson Agents; Benzothiazoles; Humans; Narcolepsy; Parkinson Disease; Pramipexole; Thiazoles | 2000 |
The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.
Topics: alpha-Synuclein; Benzothiazoles; Cell Survival; Free Radicals; Humans; Inclusion Bodies; Iron; Lewy Bodies; Mutation; Nerve Tissue Proteins; Neuroblastoma; Neurons; Oxidative Stress; Parkinson Disease; Synucleins; Thiazoles; Tumor Cells, Cultured; Ubiquitins | 2000 |
Pramipexole and somnolence.
Topics: Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Humans; Male; Narcolepsy; Parkinson Disease; Pramipexole; Thiazoles | 2000 |
Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Benzothiazoles; Dopamine Agonists; Drug Administration Schedule; Female; Humans; Hypotension, Orthostatic; Indoles; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Thiazoles | 2000 |
Dopamine agonists in early therapy for Parkinson disease: promise and problems.
Topics: Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2000 |
Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein.
Topics: alpha-Synuclein; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Humans; Immunoblotting; Kidney; Mutation; Nerve Tissue Proteins; Neurons; Oxidative Stress; Parkinson Disease; Reactive Oxygen Species; RNA, Messenger; Sulfhydryl Compounds; Synucleins; Tetrazolium Salts; Thiazoles; Transfection; Vitamin K | 2000 |
Modafinil treatment of pramipexole-associated somnolence.
Topics: Adult; Antiparkinson Agents; Benzhydryl Compounds; Benzothiazoles; Central Nervous System Stimulants; Drug Therapy, Combination; Female; Humans; Modafinil; Narcolepsy; Parkinson Disease; Pramipexole; Thiazoles; Treatment Outcome | 2000 |
Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection.
Topics: Animals; Antioxidants; Benzothiazoles; Cell Line; Cell Survival; Dopamine; Dopamine D2 Receptor Antagonists; Hydrogen Peroxide; Neurons; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; Pramipexole; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Dopamine D3; Thiazoles | 2000 |
[Dopaminergic agonists in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Benzothiazoles; Biological Availability; Bromocriptine; Catechols; Dopamine Agonists; Drug Combinations; Drug Hypersensitivity; Humans; Hypotension, Orthostatic; Indoles; Levodopa; Metabolic Clearance Rate; Nitriles; Parkinson Disease; Pergolide; Pramipexole; Selegiline; Thiazoles | 2000 |
A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzothiazoles; Cabergoline; Disorders of Excessive Somnolence; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Retrospective Studies; Thiazoles | 2001 |
Antiparkinsonian drugs and "sleep attacks".
Topics: Adverse Drug Reaction Reporting Systems; Aged; Antiparkinson Agents; Automobile Driving; Benzothiazoles; Canada; Humans; Indoles; Parkinson Disease; Pramipexole; Sleep Wake Disorders; Thiazoles | 2001 |
Current advances in Parkinson's disease.
Topics: Antidepressive Agents; Antiparkinson Agents; Benzothiazoles; Brain Stem; Catechols; Depression; Dopamine Agonists; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles | 2001 |
Efficacy and tolerability of dopamine agonists in a parkinsonian population.
Topics: Age of Onset; Aged; Aging; Benzothiazoles; Bromocriptine; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Ergolines; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Retrospective Studies; Thiazoles; Treatment Outcome | 2001 |
Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma.
Topics: 1-Methyl-4-phenylpyridinium; Alzheimer Disease; Amyloid beta-Peptides; Anti-Bacterial Agents; Aristolochic Acids; Benzothiazoles; Bongkrekic Acid; Brain; Caspase Inhibitors; Caspases; Cell Death; Dose-Response Relationship, Drug; Enzyme Inhibitors; Free Radical Scavengers; Humans; Neuroblastoma; Neurodegenerative Diseases; Neurons; Parkinson Disease; Peptide Fragments; Phenanthrenes; Pramipexole; Thiazoles; Tumor Cells, Cultured | 2002 |
Alopecia induced by dopamine agonists.
Topics: Aged; Alopecia; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Female; Humans; Indoles; Parkinson Disease; Pramipexole; Thiazoles | 2002 |
Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred.
Topics: Adult; alpha-Synuclein; Archives; Benzothiazoles; Brain; Fluorescent Antibody Technique; Fluorescent Dyes; Humans; Male; Microscopy, Immunoelectron; Nerve Degeneration; Nerve Tissue Proteins; Neurons; Parkinson Disease; Synucleins; tau Proteins; Thiazoles | 2002 |
[Dopamine agonist is effective in Parkinson disease not only against tremor. Depression is also improved].
Topics: Antiparkinson Agents; Benzothiazoles; Clinical Trials as Topic; Depressive Disorder; Dopamine Agonists; Humans; Multicenter Studies as Topic; Parkinson Disease; Pramipexole; Thiazoles; Treatment Outcome; Tremor | 2002 |
Effect of intravenous injection of chlormethiazole in spasticity, rigidity and tremor: preliminary communication.
Topics: Adolescent; Adult; Aged; Chlormethiazole; Female; Humans; Hypnotics and Sedatives; Injections, Intravenous; Male; Middle Aged; Muscle Spasticity; Paraplegia; Parkinson Disease; Spinal Cord Injuries; Thiazoles; Tremor | 1966 |